CA2137268A1 - Biodegradable controlled release melt-spun delivery system - Google Patents
Biodegradable controlled release melt-spun delivery systemInfo
- Publication number
- CA2137268A1 CA2137268A1 CA002137268A CA2137268A CA2137268A1 CA 2137268 A1 CA2137268 A1 CA 2137268A1 CA 002137268 A CA002137268 A CA 002137268A CA 2137268 A CA2137268 A CA 2137268A CA 2137268 A1 CA2137268 A1 CA 2137268A1
- Authority
- CA
- Canada
- Prior art keywords
- hydrochloride
- acid
- agents
- polymer
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/13—Burn treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/15—Suppositories
Abstract
Biodegradable controlled release delivery systems using melt-spun biodegradable polymers as carriers for bio-effecting agents such as pharmaceutical actives are disclosed. Oral dosage forms as well as implants are described.
Description
2~3'72~i~3 . 2.
W O 93/24154 ~ PC~r/US93/05307 BIODEI;P~n~R~ C~..KOLLED P~T~7`~B
MELT-S~UN DE~IVERY 8Y8TEM
BACKGRQUND OF THE lNV~ ON
This application is a continuation-in-part of 5U.S.S.N. 893,238 filed June 3, 1992.
The present invention relates to a new controlled release delivery system using melt spun biodegradable polymers as a carrier or host material for a bio-effecting agent such as a pharmaceutical active or a hormonal compound.
The convenience of administering a single dose of a medication which releases active ingredients in a controlled fashion over an extended period of time as opposed to the administration of a number of single doses lS at regular intervals has long been recognized in the pharmaceutical arts. The advantage to the patient and clinician in having consistent and uniform blood levels of medication over an extended period of time are likewise recognized. The advantages of a variety of controlled or sustained release dosage forms are well known. Among the most important advantages are: (1) increased contact time for the drug to allow for local activity in the stomach, intestine or other locus of activity; (2) increased and more efficient absorption for drugs which have specific absorption sites; (3) the ability to reduce the number of do~ages per period of time; (4) employment of less total drug; (5) minimization or elimination of local and/or systemic side effects; (6) minimization of drug accumulation associated with chronic dosage; (7) improved efficiency and safety of treatment;
(8) reduced fluctuation of drug level; and (9) better patient compliance with overall disease management.
Additionally, many experts believe sustained release drug delivery has many important non-therapeutic WO93/241~ 213~268 - PCT/US93/05307 -ramifications as well, including a financial saving to the patient in terms of less lost work days, less hospitalization and fewer visits to the physician.
It is known that certain design parameters are critical to proper drug delivery. Typically, they are:
(1) delivering the drug to the target tissue; (2) supplying the drug in the correct temporal pattern for a predetermined period of time and (3) fabricating a delivery system that provides drug in the desired spatial and temporal pattern. Controlled or sustained release drug delivery systems are intended to manipulate these parameters to achieve the aforementioned advantages when compared to conventional pharmaceutical dosing.
Controlled release o~ actives has conventionally focused on oral dosage forms such as tablets and capsules, where release of the active was accomplished by diffusion through or erosion of the matrix. Conventional formulations use waxes or hydrophilic gums as the primary drug carriers to prolong the release of the active. In wax formulations, the drug is dispersed in the wax matrix in a molten state. This method has the disadvantaga of possible decomposition and/or crystalline formation of the drug, rendering it less active or effective as a therapeutic agent. Other systems using polymeric coatings or laminates on the tablets to delay tablet disintegration and protect the active from prematurely releasing in the stomach where gastric secretions would destroy its activity. Still other systems use water-swellable hydrogel matrices to control the release of the agent by surface-to-center swelling of the matrix and subsequent diffusion of the agent. For common methods of producing controlled release products, ~ee Sustained And Controlled Release Drug Delivery Systems, Robinson, Joseph R., Ed. pp 138-171, 1978, Marcel Dekker, Inc.
N.Y., N.Y.
W O 93/24154 2~37268 P(~r/US93/05307 ....
More recently, the use of biodegradable polymers as matrices or carriers for drugs has become more prevalent.
For example, the use of biodegradable articles, such as dispensing vehicles, which are implanted in the animal, are intended to be broken down or degraded by the animal body into residues or moieties which are absorbed, metabolized or otherwise naturally removed by the body.
Early forms of these implantable polymeric devices are exemplified in U.S. Patent No. 3,882,699, which discloses a drug dispersed in a biodegradable polymeric material and shaped into a solid shape. This patent requires the use of low crystalline lactic acid polymers in order to obtain faster release of drug. Solvents are used to form homogeneous solutions of the drug/polymer mixture and extrusion, molding or compaction techn; ques are used to form the product.
Numerous drug delivery systems using polymers which are bio-eroding in the body are disclosed. For example, U.S. Patent Nos. 4,888,176, 4,891,225, 4,757,128, 4,093,709 disclose the use of polyanhydrides, poly(othoesters) and poly(orthocarbonates) to make articles for delivering agents. These patents and others deal with biodegradable synthetic polymers as drug matrices for controlled release of the drug over a sustained period of time. These delivery systems are manufactured using conventional solvent casting, extrusion or molding t~chni ques to physically entrap the drug in the polymer matrix. Solvent casting involves preparing a solution of drug and polymer using a solvent and removing the solvent to leave a residue of polymer and drug presumably in intimate physical contact. The residue can then be further processed or shaped using - conventional thermoplastic processing methods. The present invention avoids the disadvantages associated with the use of solvents by processing polymers in the substantial absence of solvents. No solvents are WO93/~154 Z13~7~8 PCT/U~93/05307 generally required to practice the invention.
Another conventional thermoplastic processing t~c-hnique involves the use of melt-spinning techn;ques.
For example, U.S. Patent No 4,335,232 to Irwin discloses melt-spinning aromatic copolyesters; and U.S. Patent No.
4,072,658 to Okamato, et al. discloses melt-spinning of polysLyLene. These conventional melt-spinning t~chni ques involve subjecting a feedstock to sust~inP~ heat treatment and are described in F. Billmeyer, Jr., Textbook Of Polymer Science, 518-522 (Wiley International Edition 2d). Conventional spinning processes require melting the polymer or dissolving the polymer in solution (an exception is the aqueous dispersion of a polymer, such as polytetrafluoroethylene), followed by removal of the liquid and sintering. In these melt-spi nni ng procedures, molten polymer is pumped at a constant rate under high pressure through a plate having a number of small holes, which is referred to as a spinneret.
Polymer is melted, usually by contacting it with a hot grid or by use of an extrusion-type screw, and passed directly to a meter pump. Filaments emerge from the spinneret into air where it begins to cool. As the fibers solidify, they are brought together and drawn to orient the fibers. In both dry spinning and wet spinning procedures, the polymer or polymer derivative is put into solution prior to forming the fiber.
All of the conventional thermoplastic processing t~c-hni ques when applied to drugs and other active agents suffer from a number of obvious drawbacks. Processing temperatures encountered in the polymeric melt stage vary with the type of polymer and are often too high to retain stability of the drug. Drug/polymer interactions or degradation of the drug may occur, rendering the drug inactive or less effective for its intended purpose.
Biodegradable polymers such as polyanhydrides require WO93/~1~ 213726~ PCT/US93/05307 higher molecular weights in order to avoid brittleness during solvent casting and maintain their structural integrity in the resultant products.
The literature discloses that release of drugs from polymer systems is ~eren~Pnt upon a number of factors.
One critical factor is the degree of crystallinity present in the polymer. The higher the degree of crystallinity, the slower the rate of degradation of the polymer and thus the slower the release of drug or active from the polymer matrix. Conversely, polymers with less crystallinity generally degrade more easily or rapidly, thereby effectuating release of the active in a shorter time. For a discussion of the effect of polymer crystallinity on drug release see "Using Biodegradable Polymers In Advanced Drug Delivery Systems", Schacht, Etiens 41, Medical Device Technology, January-February 1990; and Flory, Paul J., Principles Of Polymer ChemistrY, 5th Ed., 1966. The concern regarding crystallinity has been addressed by attempting to balance the molecular weight of the polymer with its crystalline structure to obtain the desired release rate and duration. The conventional processing t~chn;ques have not afforded practical, reproducible and cost effective methods for solving this concern.
The present invention has distinct advantages with respect to the use of crystalline polymers as compared to conventional biodegradable systems. The compositions of the present invention allow for greater amorphous character in the final product which results in a faster rate of polymer degradation and consequently a faster release of drug or active from the polymer matrix. The ability of the present invention to provide a higher degree of amphorous character to the spun matrix allows for the use of polymers which before would have been considered as having too high degree of crystallinity to ~, -~ . ~ .. F ~ . _ WO93/24154 ~ - ~ ~ PCT/US93/05307 ~
~3~ 6 be able to release in many applications. The conversion of crystalline polymers to a more amorphous state also allows for a more predictable degradation rate. The present invention thus provides compositions having a higher ratio of amorphous polymer to crystalline polymer, which provides an important advantage over conventional polymer processing. Amorphous polymers also tend to provide more uniform release characteristics as compared to crystalline polymers and enhance the bioavailability of the active.
More recently, a new method of producing substances having pharmacological properties was disclosed in U.S.
Patent No. 4,855,326. This patent discloses combining sugar with a medicament and spinning the combination into a readily water-soluble floss or fiber. In U.S. Patent No. 5,011,532, the disclosure deals with oleaginous substAnc~c such as vegetable oil, baby oil, margarine, lanolin, cocoa butter and the like, and how their lack of affinity for water is altered by mixing the oleaginous substance with sugar and melt-spinning the mixture in cotton candy spinning machines or the equivalent. As so modified, the products disperse in water forming a colloidal or pseudocolloidal dispersion.
Other disclosures which relate to spinning substances with one or more sugars are found in U.S.
Patent No. 4,873,085 issued October 10, 1989, U.S. Patent No. 5,034,421 issued July 23, 1991, U.S. Patent No.
5,028,632 issued July 2, 1991, and U.S. Patent No.
4,997,856 issued March 5, 1991. The products described in the above-mentioned patents and applications are all produced by processing in a cotton candy machine.
Illustrative of a cotton candy machine is the Econo Floss Model 3017 manufactured by Gold Medal Products Co. of Cincinnati, Ohio. The process described in the ahove-identified disclosures involve the Use of sugar(s) as a ~ W093/241~ Z~37268 PCT/US93/05307 feedstock material which is spun to produce a materialsuch as a floss, fiber, and the like. Accordingly, the technology described in the above-identified disclosures relies on the physical characteristics of sugar.
It is apparent that a need exists for a controlled release composition for delivering bio-effecting actives such as therapeutic and prophylactic agents to animals which are hA~e~ on biodegradable non-saccharide polymer carriers which can be made without the disadvantages associated with conventional thermoplastic processing and which are capable of controllably releasing the active over a pre-determined period of time at a choc~n rate.
The present invention provides such a composition, and offers an efficient and cost effective method of preparation.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure l is a graph showing the amount of vancomycin drug released from the polyglycolide polymer matrix.
Figure 2 is an enlargement of a portion of the graph in Figure l to better show the release profile in days 6-14.
SUMMARY OF THE lNV~N'l'lON
The present invention relates to unique controlled release compositions and their methods of preparation.
More particularly, the present invention relates to biodegradable controlled release compositions formed by melt-spinning a non-saccharide biodegradable polymer and a bio-effecting agent.
For ~u~oses of this invention, the following definitions shall apply:
W O 93/24154 2 1 3 7 2 6 ~ . . PC~r/U~93/05307 The term "biodegradable" shall mean the ability to be degraded by processes involving biological conditions, such as those present in the bodies of humans or other animals. More specifically, this term indicates the physical or chemical breaking down of the polymer into smaller units which are preferably innocuous, non-toxic and are readily eliminated or metabolized by the body.
The term includes the concepts of erosion and diffusion.
Erosion is generally classified either as heterogeneous or homogeneous. The former refers to surface erosion of the polymer matrix cont~;ning the active, and the latter refers to erosion beneath the surface into the body of the matrix contA i n ing the active. Biodegradation is the principle allowing for release of the active material and absorption of the degradation products. A number of factors play a role in biodegradation and hence in controlling release including, the nature of the polymer, the type of active, the geometry and surface area of the product, the ratio of matrix or carrier to active, the degree of polymer crystallinity, the process of preparing the active/polymer mixture, to name a few. It is preferred that the inventive compositions perform in response to self-regulated feedback mechAnicms in the body. Fluids in the body are the source of components which attack the polymer, allowing for erosion of the carrier material and release of the active. Such factors as hydrolysis, pH, enzymes, bile fluids and merhAn;cal forces present in the body may contribute to biodegradation. Thus, for a given application the type of polymer chosen can be tailored to fit those factors present at the site of delivery. For example, pH-sensitive polymers may be chosen if the purpose is to bypass release in the stomach and deliver sustained levels in the small intestine. On the other hand, if the composition is to be implanted in the body, such as in a closed wound, the polymer should be sufficiently stable without hydrolysis of the polymer for a desired period.
~ W O 93/24154 2~ PC~r/US93/05307 The term "controlled release" is intended to mean the release of active at a pre-selected or desired rate.
This rate will vary depending upon the application.
Desirable rates include fast or immediate release profiles as well as delayed, sust~; nP~ or sequential release. Combinations of release patterns, such as initial spiked release followed by lower levels of sustained release of active are contemplated.
The term "bio-effecting active" includes therapeutic agents such as pharmaceutical or pharmacological active agents, e.g., drugs and medicaments, as well as prophylactic agents, diagnostic agents and other chemicals or materials useful in treating or preventing conditions, infections and disease found in animals. The compositions of the present invention are particularly effective in humans and other mammals, but are intended for use in other animals such as fish and birds, or plants, insects and other organisms.
Both water-soluble and water-insoluble drugs have been found to be useful in the delivery systems covered by the invention. For purposes of this application, the terms water-soluble and water-insoluble drug will have the following definitions. "Water-soluble" drug will mean that up to 30 parts of solvent are required to completely dissolve 1 part of drug. The term "water-insoluble" drug will mean greater than 30 parts of solvent are required to dissolve 1 part of the drug. For further discussion of these terms, see USP XXII, page 1807 incorporated herein by reference. The compositions can be used to obtain specific controlled release profiles, combining aspects of immediate release, intermediate release, and sustained release in one formulation.
The term "melt-spinning" has been used in the WO93/241~ 2~3~2~8 , ~ PCT/US93/05307 ~
claims. However, in the context of the present invention "melt-spinn;ng" means subjecting solid feedstock i.e.
biodegradable polymer/bio-effecting active combinations to the combination of temperature, thermal gradients, mechAn;cal forces, flow, and flow rates during processing which is comparable to that applied to the feedstock during operation of a machine for producing cotton candy.
This is in contrast to the use of the term melt-spinning in the polymer-processing art. Conventional "melt-spinning" is used by the polymer tech~i cian to describeprocesses for extruding polymers which are held under liquid or melted conditions for comparatively long periods of time before being extruded under direct pressure through an orifice.
"Flash flow" is referred to in the present process as a phenomena which occurs when a solid carrier material (e.g., thermoplastic material) is subjected to conditions of temperature and shear sufficient to provide internal flow at a subparticle level. This condition produces a transformation of physical and/or chemical structure without degradation of the material. Internal flow occurs when the infrastructure of the material breaks down sufficiently to permit movement of the material at a subparticle level, and probably at a molecular level. At a molecular level, internal flow contemplates the movement of molecules relative to each other.
Flash-flow processing can be accomplished several ways. Flash heat and flash shear are two such processes which can be used. In the flash heat process, the feedstock material is heated sufficiently to create an internal flow condition which permits part of the feedstock to move at a subparticle level with respect to the rest of the mass and exit openings provided in the perimeter of the spinning head. The centrifugal force created in the spinning head flings the flowing feedstock W093/241~ ~37~8 ~ r~ ~ ~CT/US93/05307 material outwardly from the head æo that it reforms with a changed structure. The force required to separate and discharge flowable feedstock is only centrifugal force which results from the spinning head. The flash heat process is one process for producing an amorphous matrix such as the sugar floss used in this invention.
In the flash shear process, a shearform matrix is formed by raising the temperature of the feedstock material which includes a non-solubilized carrier to a point where the carrier such as a saccharide-based material undergoes internal flow upon application of a fluid shear force. The feedstock is advanced and ejected while in internal flow condition, and subjected to disruptive fluid shear forces to form multiple parts or masses which have morphology different from that of the original feedstock.
The multiple masses are cooled substantially immediately after contact with the fluid shear force and are permitted to continue in a free-flow condition until solidified.
The flash shear process can be carried out in an apparatus which has means for increasing the temperature of a non-solubilized feedstock and means for simultaneously advancing it for ejection. A multiple heating zone twin screw extruder can be used for increasing the temperature and advancing feedstock. The second element of the apparatus is a means for ejecting the feedstock in a condition for shearing it to provide the shearform matrix. The means for ejecting is in fluid communication with the means for increasing the temperature and is arranged at the point to receive the feedstock while it is in the internal flow conditions.
The means for ejecting the feedstock is preferably a nozzle which provides high pressure ejection of the W O 93/24154 2~3 72~8 r ~ 12 C~r/us93/05307 feedstock material. For a description of various apparati which can be used to produce the inventive delivery systems, see copen~ing U.S. Serial No. (Docket 447-65), filed October 23, 1992 entitled "Process for ~;~k;ng Shearform Matrix", which is herein incorporated by reference.
In the present invention, thermoplastic material is subjected to flash flow sufficiently to deform and pass through an opening under minimum amount of force. The force used in the present preferred embodiments of the invention is centrifugal force provided by a spinning head from which the deformed flowable material is thrown at high speed. No external force is imposed on the flowable thermoplastic material after it is flung out of the spinning head. The thermoplastic material instantaneously reforms as a solid having altered physical and/or chemical structure. The altered structure results from the forces acting on the material as it exits the head and is hurled outwardly during the brief period during which it experiences flash flow.
The flash flow phenomena of the present invention occurs in not more than one second, preferably on the order of tenth of seCo~C~ e.g., not more than about 0.4 seconds, and most preferably on the order of milliseconds 2 5 and certainly not more than 0.1 seconds. This unique phenomena can be produced by relatively high speed distribution of the thermoplastic material to an environment of elevated temperature under a constant force, such as centrifugal force, caused by high speed rotation of a continuous-wall spinning head. One example of a me~h~n;~m for producing such a combination is a cotton candy making machine. Variations of such an apparatus are contemplated for use in the present invention. The important aspect is that the flash flow phenomena be induced in a solid feedstock for rapid . `~ .3 W O 93/24154 2137~68 PC~r/US93/05307 transition to solid thermoplastic material having an altered structure from that of the feedstock.
.
Those polymers useful as carrier materials for the bio-affecting actives include non-saccharide polymers and copolymers which are substantially biocompatible and biodegradable. Mixtures of polymers as well as layers of polymers are contemplated. The polymers must be capable of undergoing melt-spin processing as defined herein.
These polymers should have a balance of hydrophobic/hydrophilic characteristics to resist attack by body fluids, e.g., hydrolysis, for a desired time, yet be degradable to allow for controlled release.
Biocompatability, low toxicity and a high degree of amorphous characteristics are important. In applications involving tissue implants, a low glass transition temperature is desirable for pliability and comfort.
Hydrolytic labile backbone or side çhA i nC contribute to the degradative process.
The present invention also relates to unique methods of preparing controlled release melt-spun delivery systems for actives including subjecting a biodegradable non-saccharide polymeric carrier and a bio-affecting active to melt-spinning to unite said polymer and active under conditions which produce a solid capable of releasing said active under conditions found in the body of an animal. A method of treatment for diseases and other conditions found in the body is also disclosed.
Such a treatment involves the administration of an effective amount of a biodegradable controlled release composition comprising a non-saccharide biodegradz~ble polymeric carrier and a bio-effecting therapeutic or prophylactic agent. The present invention also relates to novel solid sustained released delivery systems and products made therefrom obtained by subjecting a biodegradable spinnable non-saccharide host polymer and a Z13~72 . r ~ ~ ~
WO93/~1~ PCT/US93/05307 -guest bio-effecting active to flash flow processing.
DETAIT~D ~ESCRIPTION OF THE lN V~N'l'lON
Those polymers which are useful in the present invention include any melt-spinnable thermoplastic polymers which are capable of biodegrading under conditions found in the body of animals. As previously described, the polymers should be capable of being melt-spun as defined herein. The melting points and glass transition temperatures of these polymers may vary widely, as will their molecular weights. The speed, temperature and time of the melt-spinning apparatus can be adjusted accordingly to accommodate these property variations and produce a product useful for controlled release. The polymer must therefore be capable of undergoing flash flow as described herein. As previously mentioned, the polymers are proce~ according to the present invention in the substantial absence of solvent, and accomplishes the transformation from a crystalline state to an amorphous state through the flash-flow process.
Once a polymer/bio-effecting active combination has been spun, it may take a number of solid or solid-like forms such as flakes, chips, floss, fibers, ribbons and the like. These product forms can be used in that form or further modified into other delivery forms for specific application.
It is to be understood that any biodegradable thermoplastic polymer that can be subjected to melt-spinning as defined herein without being degraded, burnt or otherwise damaged, can be used as the carrier for the bio-effecting active. Melt-spinning a mixture of such polymer and active produces a trapped form of said active agent which isolates the active agent from its Z~3 ~68 W093/~1~ PCT/US93/0~307 surrol7n~;ngs yet permits slow release in the appropriate fluid environment. The principal limitation upon carrier or active is that neither be degraded or rendered substantially inactive while being melt-spun. Also, the polymer carrier and active agent should be chemically compatible.
Useful polymeric materials include polymers, copolymers, block polymers and mixtures thereof. Among the known useful polymers or polymer classes which meet the above criteria are: poly(glycolic acid) (PGA), poly(lactic acid) (PLA), polydioxanes, polyoxalates, poly(~-esters), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acids, polyurethanes, polycarbonates, polyiminocarbonates, polyamides, poly(alkyl cyanoacrylates), and mixtures and copolymers thereof. Additional useful polymers include, stereopolymers of L- and D-lactic acid, copolymers of bis(p-carboxyphenoxy) proprionic acid and sebacic acid, sebacic acid copolymers, copolymers of caprolactone, poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, copolymers of polyurethane and poly(lactic acid), copolymers of ~-amino acids, copolymers of ~-amino acids and caproic acid, copolymers of ~-benzyl glutamate and polyethylene glycol, copolymers of succinate and poly(glycols), polyphosphazene, polyhydroxy-alkanoates and mixtures thereof. Binary and ternary systems are contemplated.
Other specific polymers useful include those marketed under the Medisorb and Biodel trademarks. The 30 Me~i ~orb materials are marketed by the Dupont Company of Wilmington, Delaware and are generically identified as a - "lactide/glycolide polymer" contAining "propanoic acid, 2-hydroxy-polymer with hydroxyacetic acid." Four such polymers include Me~isorb lOOL, believed to be 100%
lactide having a melting point within the range of 338-2~8 . ~ s WO93/~154 PCT/US93/05307 -347-F (170--175-C); Medisorb lOODL, believed to be 100 glycolide having a melting point within the range of 437--455F (225-235-C); Medisorb 85:15DL, believed to be a copolymer of propionic acid, 2 hydroxypolymer and hydroxyacetic acid and having 85 mole percent lactide and 15 mole percent glycolide; and M~A;corb 50:50DL, believed to be a copolymer of propionic acid, 2-hydroxypolymer and hydroxyacetic acid and having 50 mole percent lactide and 50 mole percent glycolide.
The Biodel materials represent a family of various polyanhydrides which di~fer chemically.
Certain polymers exhibit particularly useful permeation rates for specific drugs. For example, polycaprolactones are known to have high permeation rates to steroids such as testosterone, progesterone and norgestral. Thus, a particular polymer can be chosen for its ability to release certain drugs in a particular release profile.
As previously mentioned, the present invention allows for the production of products having a high degree of amorphous character. Since the rate of degradation is known to be hindered or decreased by higher degrees of crystallinity and ~nh~nce~ or increased by higher degrees of amorphous character, the compositions of the present invention have enhanced and more predictable rates of degradation of the polymer matrix. A more rapid and controlled degradation allows for both a faster and more controlled release of the active material. The conversion of the polymers from a highly crystalline state to a relatively high amorphous state as compared to conventional polymer processing t~chn;ques provides a unique ability to use in the starting materials polymers which previously would have been considered too highly crystalline to provide 2~3~
WO93/241~ PCT/US93/05307 appropriate release profiles. Thus, not only does this benefit may of the known applications but also opens up numerous new applications for highly crystalline starting materials.
The bio-affecting active may be selected from any suitable drug, therapeutic or prophylactic agent which can be melt-spun with a selected polymer without losing substantial activity for the c-hos~ therapy. A broad range of materials are therefore useful and but for the limitations discllfise~ above, the invention contemplates the classes of water-soluble and water-insoluble actives.
Representative non-limiting classes of drugs useful include those falling into the following therapeutic categories:
ace-inhibitors; anti-anginal drugs; anti-arrhythmias;
anti-asthmatics; anti-cholesterolemics; anti-convulsants;
anti-depressants; anti-diarrhea preparations; anti-histamines; anti-hypertensive drugs; anti-infectives;
anti-inflammatory agents; anti-lipid agents; anti-manics;
anti-nauseants; anti-stroke agents; anti-thyroid preparations; anti-tumor drugs; anti-tussives; anti-uricemic drugs; anti-viral agents; acne drugs; alkaloids;
amino acid preparations; anabolic drugs; analgesics;
anesthetics; angiogenesis inhibitors; antacids;
antiarthritics; antibiotics; anticoagulants; antiemetics;
antiobesity drugs; antiparasitics; antipsychotics;
antipyretics; antispasmodics; antithrombotic drugs;
anxiolytic agents; appetite stimulants; appetite suppressants; beta blocking agents; bronchodilators;
cardiovascular agents; cerebral dilators; chelating - agents; cholecystokinin antagonists; chemotherapeutic agents; cognition activators; contraceptives; coronary dilators; cough suppressants; decongestants; deodorants;
dermatological agents; diabetes agents; diuretics;
emollients; enzymes; erythropoietic drugs; expectorants;
fertility agents; fungicides; gastro-intestinal agents;
WO 1~3/241~;4 ~ r ~ . ~ c 1~CI'/US93/05307 growth regulators; hormone replacement agents;
hyperglycemic agents; hypnotics; hypoglycemic agents;
laxatives; migrain treatments; mineral supplements;
mucolytics; narcotics; neuroleptics; neuromuscular drugs;
5 ~ATn~; nutritional additives; peripheral vaso-dilators;
polypeptides; prostaglA~i nc; psychotropics; renin inhibitors; respiratory stimulants; steroids; stimulants;
sympatholytics; thyroid preparations; tranquilizers;
uterine relaxants; vaginal preparations; vaso-constrictors; vaso-dilators; vertigo agents; vitamins;
wound healing agents.
Non-limiting examples of specific bio-effecting agents which may be useful in the present invention can be chosen from the list which follows; Mixtures of these 15 agents and their salts used for appropriate therapies are also contemplated:
acetaminophen; acetic acid; acetylsalicylic acid and its buffered form; albuterol and its sulfate; alcohol;
alkaline phosphatase; allantoin; aloe; aluminum acetate, 20 carbonate, chlorohydrate, hydroxide; alprozolam; amino acids; aminobenzoic acid; amoxicillin; ampicillin;
amsacrine; amsalog; anethole; ascorbic acid; aspartame;
atenolol; bacitracin; balsam peru; BCNU (carmustine) beclomethasone dipropionate; benzocaine; benzoic acid;
25 benzophenones; benzoyl peroxide; bethanechol; biotin;
bisacodyl; bornyl acetate; bromopheniramine maleate;
buspirone; caffeine; calamine; calcium, calcium carbonate, casinate and hydroxide; camphor; captopril;
cA~cAra sagrada; castor oil; cefaclor; cefadroxil;
c~ph~lexin; cetylalcohol; cetylpyridinium chloride;
chelated minerals; chloramphenicol; chlorcyclizine hydrochloride; chlorhexidine gluconate; chloroxylenol;
chloropentostatin; chlorpheniramine maleate;
cholestyramine resin; choline bitartrate; chondrogenic stimulating protein; cimetidine hydrochloride;
cinnamedrine hydrochloride: citalopram; citric acid;
2~37268 ~
W O 93/24154 ~ r ~; ? ~ ; PC~r/US93/05307 cocoa butter; cod liver oil: codeine and codeine phosphate; clonidine and its hydrochloride salt;
clorfibrate; cortisone acetate; ciprofloxacin HC1;
cyanocobalamin; cyclizine hydrochloride; danthron;
dexbromphen;ranime maleate; dextromethorphan hydrobromide; diazapam; dibucaine; diclofenac sodium;
digoxin; diltiazem; dimethicone; dioxybenzone;
diphenhydramine citrate; diphenhydramine hydrochloride;
docusate calicum, potassium and sodium; doxycycline hyclate; doxylamine succinate; efaroxan; enalpril;
enoxacin; erythromycin; estropipate; ethinyl estradiol;
ephedrine; epinephrine bitartrate; erythropoietin;
eucalyptol; ferrous fumarate, gluconate and sulfate;
folic acid; fosphenytoin; 5-fluorouracil (5-FU) fluoxetine HCl; furosemide; gabapentan; gentamicin;
gemfibrozil; glipizide; glycerin; glyceryl stearate;
griseofulvin; growth hormone; guaifenesin;
hexylresorcinol; hydrochloro~hi~;de; hydrocodone bitartrate; hydrocortisone and its acetate; 8-hydroxyquinoline sulfate; ibuprofen; indomethacin;inositol; insulin; iodine; ipecac; iron; isoxicam;
ketamine; koalin; lactic acid; lanolin; lecithin;
leuprolide acetate; li~oc~ine and its hydrochloride salt;
lifinopril; liotrix; lovastatin; luteinizing hormone;
LHRH (luteinizing hormone releasing hormone); magnesium carbonate, hydroxide, salicylate, trisilocate; mefenamic acid; meclofenanic acid; meclofenamate sodium;
medroxyprogesterone acetate; methenamine mandelate;
menthol; meperidine hydrochloride; metaproterenol sulfate; methyl nicotinate; methyl salicylate;
methylcellulose; methsuximide; metronidazole and its - hydrochloride; metoprolol tartrate; miconazole nitrate;
mineral oil; minoxidil; morphine; naproxen and its sodium salt; nifedipine; neomycin sulfate; niacin; niacinamide;
nicotine; nicotinamide; nitroglycerin; no~o~ynol-9;
noreth;n~one and its acetate; nystatin; octoxynol;
octoxynol 9; octyl dimethyl PABA; octyl methoxycinnamate;
r ~
W O 93/24154 2 ~ 3 ~ 8 PC~r/US93/05307 omega-3 polyunsaturated fatty acids; omeprazole; oxolinic acid; oxybenzone; oxtriphylline; para-aminobenzoic acid (PABA); padimate O; paramethadione; pentastatin;
peppermint oil; pentaerythriol tetranitrate;
pentobarbital sodium; rhe~; ramine maleate; phenobarbital;
phenol; phenolphthalein; phenylephrine hydrochloride;
phenylpropanolamine and its hydrochloride salt;
phenytoin; phenelzine sulfate; pirmenol; piroxicam;
polymycin B sulfate; potassium chloride and nitrate;
prazepam; proc~inAmide hydrochloride; procaterol;
propoxyphene and its HCl salt; propoxyphene napsylate;
pramiracetin; pramoxine and its hydrochloride salt;
propronolol HCl; pseudoephedrine hydrochloride and sulfate; pyridoxine; quinapril; quinidine gluconate and sulfate; quinestrol; ralitoline; ranitadine; resorcinol;
riboflavin; salicylic acid; sesame oil; shark liver oil;
simethicone; sodium bicarbonate, citrate and fluoride;
sodium monofluorophosphate; sucralfate; sulfanethoxazole;
sulfasalazine; sulfur; tacrine and its HCl salt;
theophylline; terfenidine; thioperidone; trimethrexate;
triazolam; timolol maleate; tretinoin; tetracycline hydrochloride; tolmetin; tolnaftate; triclosan;
triprolidine hydrochloride; undecylenic acid; vancomycin;
verapamil HCl; vidaribine phosphate; vitamins A, B, C, D, B1, B2, B6, B12, E, K; witch hazel; xylometazoline hydrochloride; zinc; zinc sulfate; zinc undecylenate.
Drugs which are chemically linked to the polymer, e.g. macromolecular prodrugs are contemplated.
Useful dosage forms include without limitation oral forms such as tablets, capsules, beads, granules, aggregates, syrups, powders, gels, solids, semi-solids, suspensions and liquids. Injectable forms, lotions, transdermal delivery systems including dermal patches, implantable forms or devices, aerosols or nasal mists, suppositories, salves and ointments are also useful.
Z13~7268 WO93/~154 ; ~ i PCT/US93/05307 The inventive compositions have great versatility in their application. Of particular utility however, is the administration of bio-effecting agent to site-specific localities. For example, the controlled release compositions of the present invention can be used as the suture or component of a suture, i.e. threads of a multi-filament ~Lu~e, for wounds. There compositions can be used in steri-strip wound closure materials such as dressings and the like. The compositions can be used for wound management such as by direct application to burns, abrasions, skin diseases or infections and the like.
Other uses such as packing agents for nasal wounds or other open wounds are also contemplated. The packing agents can, for example, also contain blood clotting factors such as proconvertin, plasma thromboplastin, Stuart factor, Vitamin K, fibrinogen, drugs such as phytonadione or hormones such as estrogen.
In certain preferred embodiments, a growth regulator, such as a human somatatropin, a bovine somatatropin or a porcine somatatropin, is incorporated in the non-saccharide polymer. The biodegradable polymers which are melt-spun together with human somatotropin can be effectively used in tissue cultures to promote growth of human tissue. The growth of cells from fetal tissue or foreskin tissue can be stimulated by the gradual release of the hormone from the biodegradable polymer. The biodegradable polymer contA i n ing the growth hormone can be in the form of fibers or it can be material obtained by placing a support close to the spinning head to collect the material on the support - while it is still in its flowable state. Where a support is coated with such biodegradable polymer containing the hormone, the cells to be grown can be placed over the coated support to form tissue segments or patches which can be used for skin grafts and the like. Cartilage tissues can also be grown by similar procedures.
WO93/~154 2~ 8~ PCT/US93/05307 In applications involving treatment of ruminants, if the dosage form is to be administered orally, the polymer must provide a protective barrier against the fluids of the rumen and allow for passage to the abomasum where polymeric degradation and concomitant release of active can occur over time. This generally means that the polymeric matrix or carrier is designed to be resistant to pH>5 but slowly degraded at pH<3.5.
In the case of oral administration of actives, such as insulin, which are destroyed in gastric juices, the polymer must provide a similar protective and delivery function. Of course, alternatives to oral a~ ;stration include biodegradable implants which are designed to deliver the appropriate therapeutic dose for the specific condition treated.
A variety of additives can be incorporated into the inventive compositions for their inten~ functions.
Their additives are generally added in minor amounts.
Examples of classes of additives include excipients, lubricants, buffering agents, disintegrating agents, stabilizers, foaming agents, pigments, coloring agents, fillers, bulking agents, sweetening agents, flavoring agents, fragrances, release modifiers, adjuvants, plasticizers, flow accelerators, polyols, granulating agents, diluents, binders, buffers, absorbents, glidants, adhesives, antiadherents, acidulants, softeners, resins, demulcents, solvents, surfactants, emulsifiers, elastomers and mixtures thereof.
Useful additives include, for example, gelatin, vegetable proteins such as sunflower protein, soybean proteins r cotton seed proteins, peanut proteins, rape seed proteins, blood proteins, egg proteins, acrylated proteins; water-soluble polysaccharides such as alginates, carrag~enAn~ guar gum, agar-agar, gum arabic 2~37Z6~
W O 93/24154 ' `- PC~r/US93/05307 and related gums (gum ghatti, gum karaya, gum tragacanth), pectin; water-soluble derivatives of cellulose: alkylcelluloses, hydroxyalkylcelluloses and hydroxyalkylalkylcelluloses, such as methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxpropylmethylcellulose, hydloxL~Lylmethylcellulose, cellulose esters and hydroxyalkylcellulose esters such as: cellulose acetate phthalate (CAP), carboxyalkylcelluloses, carboxyalkylalkylcelluloses, carboxyalkylcellulose esters such as carboxymethylcellulose and their alkali metal salts;
water-soluble synthetic polymers such as polyacrylic acids and polyacrylic acid esters, polymethacrylic acids and polymethacrylic acid esters, polyvinylacetates, polyvinylalcohols, polyvinylacetatephthalates (PVAP), polyvinylpyrrolidone (PVP), PVP/vinyl acetate copolymer, and polycrotonic acids; also suitable are phthalated gelatin, gelatin succinate, crosslinked gelatin, shellac, water-soluble chemical derivatives of starch, cationically modified acrylates and methacrylates possessing, for example, a tertiary or guaternary amino group, such as the diethylaminoethyl group, which may be quaternized if desired; and other similar polymers.
Processing aids such as mono- and triglycerides are useful as well. In certain preferred embodiments, saccharides such as sucrose, maltodextrin, polydextrose, lactose, maltose and the like are added to the non-saccharide polymer in amounts of about 1 to about 35% by weight of the non-saccharide polymer. The bioeffecting - agent is mixed with the saccharide before spinning and in certain embodiments can be present in both the saccharide material and the non-saccharide carrier. Upon sp; nn; ng, the saccharide tends to form pockets or cavities within the non-saccharide polymer which results in a material where the bioeffecting agent is released in accordance WO93/~1~ 2~372~8 PCT/US93/05307 0 with diffusion gradients from the relatively soluble saccharides and in accordance with the degradation properties of the non-saccharide polymer when the bioactive compound is incorporated in such polymer.
Further additives may be inorganic fillers, such as the oxides of magnesium, aluminum, silicon, titanium, and the like preferably in a concentration range of about 0.02 to about 3% by weight and preferably about 0.02 to about 1% based on the weight of all components.
Further examples of additives are plasticizers which include polyalkylene oxides, such as polyethylene glycols, polypropylene glycols, polyethylene-propylene glycols; organic plasticizers with lcw molecular weights, such as glycerol, glycerol monoacetate, diacetate or triacetate; propylene glycol, sorbitol, sodium diethylsulfosuccinate, triethyl citrate, tributyl citrate, and the like.
Examples of coloring agents include known azo dyes, organic or inorganic pigments, or coloring agents of natural origin. Inorganic pigments are preferred, such as the oxides of iron or titanium.
one particularly useful class of additives which can be incorporated into the spun matrix of the present compositions include radio opaque materials. These materials can be used to monitor the position of the controlled release composition via x-rays, and in cases where non-biodegradable material is present, such as carbon fibers, these will remain in the body subsequent to degradation of the polymer as a marker to show the site of the wound of the cite of treatment.
Prior to forming the polymer and drug mixture, the polymers were cryG~Lou~.d to reduce the particle size and WO93/241~ 2137~8 PCT/US93/05307 facilitate spinning. Cryogrinding was conducted under liquid nitrogen in a RETSCH Model ZM-1 Ultra Centrifugal Mill, 2.0 mm sieve with 12 tooth rotor.
The amount of bio-effecting active present is dependent upon the treatment indicated. The bio-effecting/polymer ratios will vary accordingly. In general, however, the polymer is present in amounts of about 50 to 99% by weight and preferably about 75 to 90%.
The balance of the composition is active, with various amounts of additives as previously mentioned.
F~AMpLEs Four biodegradable polymers were melt-spun in combination with various drugs to sl~cc~ssfully make compositions useful in the present invention. The polymers used were (1) polyglycolide, a copolymer of L(-) lactide (69.29%) and glycolide (30.05%), (2) p-dioxane, (3) polycaprolactone and (4) polysabacic acid. These polymers were used to encapsulate the drugs vancomycin, gentamicin, tolmetin, diphenhydramine, ibuprofen and insulin, as shown in Table I below.
Each composition was formed by first mixing the drug and a processing aid (medium chain triglyceride supplied by Huls America under the name Miglycol 812) in a mortar and pestle. The biodegradable polymer was then slowly added with continuous mixing. The mixtures were preferably homogeneous.
Each of the example mixtures were spun on an Econo Floss spinning machine which was modified to provide for variable temperature of the heating ribbon and variable speed of the rotating head. The spinning head was 5.5 inches in diameter having slits in the outer containment band which were 3-5mm long by 0.5-0.75mm wide. Where a WO93~ 3~6~ PCr/US93/05307 Kapton0 liner is specified, it is a band of Kapton polymer (polyimide available from DuPont) material inserted between the heating element and the outer containment band with 0.042" holes in the Kapton~ band aligned with the slots in the outer containment band.
Table I also indicates the relative weight percents of the melt-spun components as well as the rotational speed (RPM) and temperature of the spinning head.
W O 93/24154 ~ PC~r/US93/05307 BIODEI;P~n~R~ C~..KOLLED P~T~7`~B
MELT-S~UN DE~IVERY 8Y8TEM
BACKGRQUND OF THE lNV~ ON
This application is a continuation-in-part of 5U.S.S.N. 893,238 filed June 3, 1992.
The present invention relates to a new controlled release delivery system using melt spun biodegradable polymers as a carrier or host material for a bio-effecting agent such as a pharmaceutical active or a hormonal compound.
The convenience of administering a single dose of a medication which releases active ingredients in a controlled fashion over an extended period of time as opposed to the administration of a number of single doses lS at regular intervals has long been recognized in the pharmaceutical arts. The advantage to the patient and clinician in having consistent and uniform blood levels of medication over an extended period of time are likewise recognized. The advantages of a variety of controlled or sustained release dosage forms are well known. Among the most important advantages are: (1) increased contact time for the drug to allow for local activity in the stomach, intestine or other locus of activity; (2) increased and more efficient absorption for drugs which have specific absorption sites; (3) the ability to reduce the number of do~ages per period of time; (4) employment of less total drug; (5) minimization or elimination of local and/or systemic side effects; (6) minimization of drug accumulation associated with chronic dosage; (7) improved efficiency and safety of treatment;
(8) reduced fluctuation of drug level; and (9) better patient compliance with overall disease management.
Additionally, many experts believe sustained release drug delivery has many important non-therapeutic WO93/241~ 213~268 - PCT/US93/05307 -ramifications as well, including a financial saving to the patient in terms of less lost work days, less hospitalization and fewer visits to the physician.
It is known that certain design parameters are critical to proper drug delivery. Typically, they are:
(1) delivering the drug to the target tissue; (2) supplying the drug in the correct temporal pattern for a predetermined period of time and (3) fabricating a delivery system that provides drug in the desired spatial and temporal pattern. Controlled or sustained release drug delivery systems are intended to manipulate these parameters to achieve the aforementioned advantages when compared to conventional pharmaceutical dosing.
Controlled release o~ actives has conventionally focused on oral dosage forms such as tablets and capsules, where release of the active was accomplished by diffusion through or erosion of the matrix. Conventional formulations use waxes or hydrophilic gums as the primary drug carriers to prolong the release of the active. In wax formulations, the drug is dispersed in the wax matrix in a molten state. This method has the disadvantaga of possible decomposition and/or crystalline formation of the drug, rendering it less active or effective as a therapeutic agent. Other systems using polymeric coatings or laminates on the tablets to delay tablet disintegration and protect the active from prematurely releasing in the stomach where gastric secretions would destroy its activity. Still other systems use water-swellable hydrogel matrices to control the release of the agent by surface-to-center swelling of the matrix and subsequent diffusion of the agent. For common methods of producing controlled release products, ~ee Sustained And Controlled Release Drug Delivery Systems, Robinson, Joseph R., Ed. pp 138-171, 1978, Marcel Dekker, Inc.
N.Y., N.Y.
W O 93/24154 2~37268 P(~r/US93/05307 ....
More recently, the use of biodegradable polymers as matrices or carriers for drugs has become more prevalent.
For example, the use of biodegradable articles, such as dispensing vehicles, which are implanted in the animal, are intended to be broken down or degraded by the animal body into residues or moieties which are absorbed, metabolized or otherwise naturally removed by the body.
Early forms of these implantable polymeric devices are exemplified in U.S. Patent No. 3,882,699, which discloses a drug dispersed in a biodegradable polymeric material and shaped into a solid shape. This patent requires the use of low crystalline lactic acid polymers in order to obtain faster release of drug. Solvents are used to form homogeneous solutions of the drug/polymer mixture and extrusion, molding or compaction techn; ques are used to form the product.
Numerous drug delivery systems using polymers which are bio-eroding in the body are disclosed. For example, U.S. Patent Nos. 4,888,176, 4,891,225, 4,757,128, 4,093,709 disclose the use of polyanhydrides, poly(othoesters) and poly(orthocarbonates) to make articles for delivering agents. These patents and others deal with biodegradable synthetic polymers as drug matrices for controlled release of the drug over a sustained period of time. These delivery systems are manufactured using conventional solvent casting, extrusion or molding t~chni ques to physically entrap the drug in the polymer matrix. Solvent casting involves preparing a solution of drug and polymer using a solvent and removing the solvent to leave a residue of polymer and drug presumably in intimate physical contact. The residue can then be further processed or shaped using - conventional thermoplastic processing methods. The present invention avoids the disadvantages associated with the use of solvents by processing polymers in the substantial absence of solvents. No solvents are WO93/~154 Z13~7~8 PCT/U~93/05307 generally required to practice the invention.
Another conventional thermoplastic processing t~c-hnique involves the use of melt-spinning techn;ques.
For example, U.S. Patent No 4,335,232 to Irwin discloses melt-spinning aromatic copolyesters; and U.S. Patent No.
4,072,658 to Okamato, et al. discloses melt-spinning of polysLyLene. These conventional melt-spinning t~chni ques involve subjecting a feedstock to sust~inP~ heat treatment and are described in F. Billmeyer, Jr., Textbook Of Polymer Science, 518-522 (Wiley International Edition 2d). Conventional spinning processes require melting the polymer or dissolving the polymer in solution (an exception is the aqueous dispersion of a polymer, such as polytetrafluoroethylene), followed by removal of the liquid and sintering. In these melt-spi nni ng procedures, molten polymer is pumped at a constant rate under high pressure through a plate having a number of small holes, which is referred to as a spinneret.
Polymer is melted, usually by contacting it with a hot grid or by use of an extrusion-type screw, and passed directly to a meter pump. Filaments emerge from the spinneret into air where it begins to cool. As the fibers solidify, they are brought together and drawn to orient the fibers. In both dry spinning and wet spinning procedures, the polymer or polymer derivative is put into solution prior to forming the fiber.
All of the conventional thermoplastic processing t~c-hni ques when applied to drugs and other active agents suffer from a number of obvious drawbacks. Processing temperatures encountered in the polymeric melt stage vary with the type of polymer and are often too high to retain stability of the drug. Drug/polymer interactions or degradation of the drug may occur, rendering the drug inactive or less effective for its intended purpose.
Biodegradable polymers such as polyanhydrides require WO93/~1~ 213726~ PCT/US93/05307 higher molecular weights in order to avoid brittleness during solvent casting and maintain their structural integrity in the resultant products.
The literature discloses that release of drugs from polymer systems is ~eren~Pnt upon a number of factors.
One critical factor is the degree of crystallinity present in the polymer. The higher the degree of crystallinity, the slower the rate of degradation of the polymer and thus the slower the release of drug or active from the polymer matrix. Conversely, polymers with less crystallinity generally degrade more easily or rapidly, thereby effectuating release of the active in a shorter time. For a discussion of the effect of polymer crystallinity on drug release see "Using Biodegradable Polymers In Advanced Drug Delivery Systems", Schacht, Etiens 41, Medical Device Technology, January-February 1990; and Flory, Paul J., Principles Of Polymer ChemistrY, 5th Ed., 1966. The concern regarding crystallinity has been addressed by attempting to balance the molecular weight of the polymer with its crystalline structure to obtain the desired release rate and duration. The conventional processing t~chn;ques have not afforded practical, reproducible and cost effective methods for solving this concern.
The present invention has distinct advantages with respect to the use of crystalline polymers as compared to conventional biodegradable systems. The compositions of the present invention allow for greater amorphous character in the final product which results in a faster rate of polymer degradation and consequently a faster release of drug or active from the polymer matrix. The ability of the present invention to provide a higher degree of amphorous character to the spun matrix allows for the use of polymers which before would have been considered as having too high degree of crystallinity to ~, -~ . ~ .. F ~ . _ WO93/24154 ~ - ~ ~ PCT/US93/05307 ~
~3~ 6 be able to release in many applications. The conversion of crystalline polymers to a more amorphous state also allows for a more predictable degradation rate. The present invention thus provides compositions having a higher ratio of amorphous polymer to crystalline polymer, which provides an important advantage over conventional polymer processing. Amorphous polymers also tend to provide more uniform release characteristics as compared to crystalline polymers and enhance the bioavailability of the active.
More recently, a new method of producing substances having pharmacological properties was disclosed in U.S.
Patent No. 4,855,326. This patent discloses combining sugar with a medicament and spinning the combination into a readily water-soluble floss or fiber. In U.S. Patent No. 5,011,532, the disclosure deals with oleaginous substAnc~c such as vegetable oil, baby oil, margarine, lanolin, cocoa butter and the like, and how their lack of affinity for water is altered by mixing the oleaginous substance with sugar and melt-spinning the mixture in cotton candy spinning machines or the equivalent. As so modified, the products disperse in water forming a colloidal or pseudocolloidal dispersion.
Other disclosures which relate to spinning substances with one or more sugars are found in U.S.
Patent No. 4,873,085 issued October 10, 1989, U.S. Patent No. 5,034,421 issued July 23, 1991, U.S. Patent No.
5,028,632 issued July 2, 1991, and U.S. Patent No.
4,997,856 issued March 5, 1991. The products described in the above-mentioned patents and applications are all produced by processing in a cotton candy machine.
Illustrative of a cotton candy machine is the Econo Floss Model 3017 manufactured by Gold Medal Products Co. of Cincinnati, Ohio. The process described in the ahove-identified disclosures involve the Use of sugar(s) as a ~ W093/241~ Z~37268 PCT/US93/05307 feedstock material which is spun to produce a materialsuch as a floss, fiber, and the like. Accordingly, the technology described in the above-identified disclosures relies on the physical characteristics of sugar.
It is apparent that a need exists for a controlled release composition for delivering bio-effecting actives such as therapeutic and prophylactic agents to animals which are hA~e~ on biodegradable non-saccharide polymer carriers which can be made without the disadvantages associated with conventional thermoplastic processing and which are capable of controllably releasing the active over a pre-determined period of time at a choc~n rate.
The present invention provides such a composition, and offers an efficient and cost effective method of preparation.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure l is a graph showing the amount of vancomycin drug released from the polyglycolide polymer matrix.
Figure 2 is an enlargement of a portion of the graph in Figure l to better show the release profile in days 6-14.
SUMMARY OF THE lNV~N'l'lON
The present invention relates to unique controlled release compositions and their methods of preparation.
More particularly, the present invention relates to biodegradable controlled release compositions formed by melt-spinning a non-saccharide biodegradable polymer and a bio-effecting agent.
For ~u~oses of this invention, the following definitions shall apply:
W O 93/24154 2 1 3 7 2 6 ~ . . PC~r/U~93/05307 The term "biodegradable" shall mean the ability to be degraded by processes involving biological conditions, such as those present in the bodies of humans or other animals. More specifically, this term indicates the physical or chemical breaking down of the polymer into smaller units which are preferably innocuous, non-toxic and are readily eliminated or metabolized by the body.
The term includes the concepts of erosion and diffusion.
Erosion is generally classified either as heterogeneous or homogeneous. The former refers to surface erosion of the polymer matrix cont~;ning the active, and the latter refers to erosion beneath the surface into the body of the matrix contA i n ing the active. Biodegradation is the principle allowing for release of the active material and absorption of the degradation products. A number of factors play a role in biodegradation and hence in controlling release including, the nature of the polymer, the type of active, the geometry and surface area of the product, the ratio of matrix or carrier to active, the degree of polymer crystallinity, the process of preparing the active/polymer mixture, to name a few. It is preferred that the inventive compositions perform in response to self-regulated feedback mechAnicms in the body. Fluids in the body are the source of components which attack the polymer, allowing for erosion of the carrier material and release of the active. Such factors as hydrolysis, pH, enzymes, bile fluids and merhAn;cal forces present in the body may contribute to biodegradation. Thus, for a given application the type of polymer chosen can be tailored to fit those factors present at the site of delivery. For example, pH-sensitive polymers may be chosen if the purpose is to bypass release in the stomach and deliver sustained levels in the small intestine. On the other hand, if the composition is to be implanted in the body, such as in a closed wound, the polymer should be sufficiently stable without hydrolysis of the polymer for a desired period.
~ W O 93/24154 2~ PC~r/US93/05307 The term "controlled release" is intended to mean the release of active at a pre-selected or desired rate.
This rate will vary depending upon the application.
Desirable rates include fast or immediate release profiles as well as delayed, sust~; nP~ or sequential release. Combinations of release patterns, such as initial spiked release followed by lower levels of sustained release of active are contemplated.
The term "bio-effecting active" includes therapeutic agents such as pharmaceutical or pharmacological active agents, e.g., drugs and medicaments, as well as prophylactic agents, diagnostic agents and other chemicals or materials useful in treating or preventing conditions, infections and disease found in animals. The compositions of the present invention are particularly effective in humans and other mammals, but are intended for use in other animals such as fish and birds, or plants, insects and other organisms.
Both water-soluble and water-insoluble drugs have been found to be useful in the delivery systems covered by the invention. For purposes of this application, the terms water-soluble and water-insoluble drug will have the following definitions. "Water-soluble" drug will mean that up to 30 parts of solvent are required to completely dissolve 1 part of drug. The term "water-insoluble" drug will mean greater than 30 parts of solvent are required to dissolve 1 part of the drug. For further discussion of these terms, see USP XXII, page 1807 incorporated herein by reference. The compositions can be used to obtain specific controlled release profiles, combining aspects of immediate release, intermediate release, and sustained release in one formulation.
The term "melt-spinning" has been used in the WO93/241~ 2~3~2~8 , ~ PCT/US93/05307 ~
claims. However, in the context of the present invention "melt-spinn;ng" means subjecting solid feedstock i.e.
biodegradable polymer/bio-effecting active combinations to the combination of temperature, thermal gradients, mechAn;cal forces, flow, and flow rates during processing which is comparable to that applied to the feedstock during operation of a machine for producing cotton candy.
This is in contrast to the use of the term melt-spinning in the polymer-processing art. Conventional "melt-spinning" is used by the polymer tech~i cian to describeprocesses for extruding polymers which are held under liquid or melted conditions for comparatively long periods of time before being extruded under direct pressure through an orifice.
"Flash flow" is referred to in the present process as a phenomena which occurs when a solid carrier material (e.g., thermoplastic material) is subjected to conditions of temperature and shear sufficient to provide internal flow at a subparticle level. This condition produces a transformation of physical and/or chemical structure without degradation of the material. Internal flow occurs when the infrastructure of the material breaks down sufficiently to permit movement of the material at a subparticle level, and probably at a molecular level. At a molecular level, internal flow contemplates the movement of molecules relative to each other.
Flash-flow processing can be accomplished several ways. Flash heat and flash shear are two such processes which can be used. In the flash heat process, the feedstock material is heated sufficiently to create an internal flow condition which permits part of the feedstock to move at a subparticle level with respect to the rest of the mass and exit openings provided in the perimeter of the spinning head. The centrifugal force created in the spinning head flings the flowing feedstock W093/241~ ~37~8 ~ r~ ~ ~CT/US93/05307 material outwardly from the head æo that it reforms with a changed structure. The force required to separate and discharge flowable feedstock is only centrifugal force which results from the spinning head. The flash heat process is one process for producing an amorphous matrix such as the sugar floss used in this invention.
In the flash shear process, a shearform matrix is formed by raising the temperature of the feedstock material which includes a non-solubilized carrier to a point where the carrier such as a saccharide-based material undergoes internal flow upon application of a fluid shear force. The feedstock is advanced and ejected while in internal flow condition, and subjected to disruptive fluid shear forces to form multiple parts or masses which have morphology different from that of the original feedstock.
The multiple masses are cooled substantially immediately after contact with the fluid shear force and are permitted to continue in a free-flow condition until solidified.
The flash shear process can be carried out in an apparatus which has means for increasing the temperature of a non-solubilized feedstock and means for simultaneously advancing it for ejection. A multiple heating zone twin screw extruder can be used for increasing the temperature and advancing feedstock. The second element of the apparatus is a means for ejecting the feedstock in a condition for shearing it to provide the shearform matrix. The means for ejecting is in fluid communication with the means for increasing the temperature and is arranged at the point to receive the feedstock while it is in the internal flow conditions.
The means for ejecting the feedstock is preferably a nozzle which provides high pressure ejection of the W O 93/24154 2~3 72~8 r ~ 12 C~r/us93/05307 feedstock material. For a description of various apparati which can be used to produce the inventive delivery systems, see copen~ing U.S. Serial No. (Docket 447-65), filed October 23, 1992 entitled "Process for ~;~k;ng Shearform Matrix", which is herein incorporated by reference.
In the present invention, thermoplastic material is subjected to flash flow sufficiently to deform and pass through an opening under minimum amount of force. The force used in the present preferred embodiments of the invention is centrifugal force provided by a spinning head from which the deformed flowable material is thrown at high speed. No external force is imposed on the flowable thermoplastic material after it is flung out of the spinning head. The thermoplastic material instantaneously reforms as a solid having altered physical and/or chemical structure. The altered structure results from the forces acting on the material as it exits the head and is hurled outwardly during the brief period during which it experiences flash flow.
The flash flow phenomena of the present invention occurs in not more than one second, preferably on the order of tenth of seCo~C~ e.g., not more than about 0.4 seconds, and most preferably on the order of milliseconds 2 5 and certainly not more than 0.1 seconds. This unique phenomena can be produced by relatively high speed distribution of the thermoplastic material to an environment of elevated temperature under a constant force, such as centrifugal force, caused by high speed rotation of a continuous-wall spinning head. One example of a me~h~n;~m for producing such a combination is a cotton candy making machine. Variations of such an apparatus are contemplated for use in the present invention. The important aspect is that the flash flow phenomena be induced in a solid feedstock for rapid . `~ .3 W O 93/24154 2137~68 PC~r/US93/05307 transition to solid thermoplastic material having an altered structure from that of the feedstock.
.
Those polymers useful as carrier materials for the bio-affecting actives include non-saccharide polymers and copolymers which are substantially biocompatible and biodegradable. Mixtures of polymers as well as layers of polymers are contemplated. The polymers must be capable of undergoing melt-spin processing as defined herein.
These polymers should have a balance of hydrophobic/hydrophilic characteristics to resist attack by body fluids, e.g., hydrolysis, for a desired time, yet be degradable to allow for controlled release.
Biocompatability, low toxicity and a high degree of amorphous characteristics are important. In applications involving tissue implants, a low glass transition temperature is desirable for pliability and comfort.
Hydrolytic labile backbone or side çhA i nC contribute to the degradative process.
The present invention also relates to unique methods of preparing controlled release melt-spun delivery systems for actives including subjecting a biodegradable non-saccharide polymeric carrier and a bio-affecting active to melt-spinning to unite said polymer and active under conditions which produce a solid capable of releasing said active under conditions found in the body of an animal. A method of treatment for diseases and other conditions found in the body is also disclosed.
Such a treatment involves the administration of an effective amount of a biodegradable controlled release composition comprising a non-saccharide biodegradz~ble polymeric carrier and a bio-effecting therapeutic or prophylactic agent. The present invention also relates to novel solid sustained released delivery systems and products made therefrom obtained by subjecting a biodegradable spinnable non-saccharide host polymer and a Z13~72 . r ~ ~ ~
WO93/~1~ PCT/US93/05307 -guest bio-effecting active to flash flow processing.
DETAIT~D ~ESCRIPTION OF THE lN V~N'l'lON
Those polymers which are useful in the present invention include any melt-spinnable thermoplastic polymers which are capable of biodegrading under conditions found in the body of animals. As previously described, the polymers should be capable of being melt-spun as defined herein. The melting points and glass transition temperatures of these polymers may vary widely, as will their molecular weights. The speed, temperature and time of the melt-spinning apparatus can be adjusted accordingly to accommodate these property variations and produce a product useful for controlled release. The polymer must therefore be capable of undergoing flash flow as described herein. As previously mentioned, the polymers are proce~ according to the present invention in the substantial absence of solvent, and accomplishes the transformation from a crystalline state to an amorphous state through the flash-flow process.
Once a polymer/bio-effecting active combination has been spun, it may take a number of solid or solid-like forms such as flakes, chips, floss, fibers, ribbons and the like. These product forms can be used in that form or further modified into other delivery forms for specific application.
It is to be understood that any biodegradable thermoplastic polymer that can be subjected to melt-spinning as defined herein without being degraded, burnt or otherwise damaged, can be used as the carrier for the bio-effecting active. Melt-spinning a mixture of such polymer and active produces a trapped form of said active agent which isolates the active agent from its Z~3 ~68 W093/~1~ PCT/US93/0~307 surrol7n~;ngs yet permits slow release in the appropriate fluid environment. The principal limitation upon carrier or active is that neither be degraded or rendered substantially inactive while being melt-spun. Also, the polymer carrier and active agent should be chemically compatible.
Useful polymeric materials include polymers, copolymers, block polymers and mixtures thereof. Among the known useful polymers or polymer classes which meet the above criteria are: poly(glycolic acid) (PGA), poly(lactic acid) (PLA), polydioxanes, polyoxalates, poly(~-esters), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acids, polyurethanes, polycarbonates, polyiminocarbonates, polyamides, poly(alkyl cyanoacrylates), and mixtures and copolymers thereof. Additional useful polymers include, stereopolymers of L- and D-lactic acid, copolymers of bis(p-carboxyphenoxy) proprionic acid and sebacic acid, sebacic acid copolymers, copolymers of caprolactone, poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, copolymers of polyurethane and poly(lactic acid), copolymers of ~-amino acids, copolymers of ~-amino acids and caproic acid, copolymers of ~-benzyl glutamate and polyethylene glycol, copolymers of succinate and poly(glycols), polyphosphazene, polyhydroxy-alkanoates and mixtures thereof. Binary and ternary systems are contemplated.
Other specific polymers useful include those marketed under the Medisorb and Biodel trademarks. The 30 Me~i ~orb materials are marketed by the Dupont Company of Wilmington, Delaware and are generically identified as a - "lactide/glycolide polymer" contAining "propanoic acid, 2-hydroxy-polymer with hydroxyacetic acid." Four such polymers include Me~isorb lOOL, believed to be 100%
lactide having a melting point within the range of 338-2~8 . ~ s WO93/~154 PCT/US93/05307 -347-F (170--175-C); Medisorb lOODL, believed to be 100 glycolide having a melting point within the range of 437--455F (225-235-C); Medisorb 85:15DL, believed to be a copolymer of propionic acid, 2 hydroxypolymer and hydroxyacetic acid and having 85 mole percent lactide and 15 mole percent glycolide; and M~A;corb 50:50DL, believed to be a copolymer of propionic acid, 2-hydroxypolymer and hydroxyacetic acid and having 50 mole percent lactide and 50 mole percent glycolide.
The Biodel materials represent a family of various polyanhydrides which di~fer chemically.
Certain polymers exhibit particularly useful permeation rates for specific drugs. For example, polycaprolactones are known to have high permeation rates to steroids such as testosterone, progesterone and norgestral. Thus, a particular polymer can be chosen for its ability to release certain drugs in a particular release profile.
As previously mentioned, the present invention allows for the production of products having a high degree of amorphous character. Since the rate of degradation is known to be hindered or decreased by higher degrees of crystallinity and ~nh~nce~ or increased by higher degrees of amorphous character, the compositions of the present invention have enhanced and more predictable rates of degradation of the polymer matrix. A more rapid and controlled degradation allows for both a faster and more controlled release of the active material. The conversion of the polymers from a highly crystalline state to a relatively high amorphous state as compared to conventional polymer processing t~chn;ques provides a unique ability to use in the starting materials polymers which previously would have been considered too highly crystalline to provide 2~3~
WO93/241~ PCT/US93/05307 appropriate release profiles. Thus, not only does this benefit may of the known applications but also opens up numerous new applications for highly crystalline starting materials.
The bio-affecting active may be selected from any suitable drug, therapeutic or prophylactic agent which can be melt-spun with a selected polymer without losing substantial activity for the c-hos~ therapy. A broad range of materials are therefore useful and but for the limitations discllfise~ above, the invention contemplates the classes of water-soluble and water-insoluble actives.
Representative non-limiting classes of drugs useful include those falling into the following therapeutic categories:
ace-inhibitors; anti-anginal drugs; anti-arrhythmias;
anti-asthmatics; anti-cholesterolemics; anti-convulsants;
anti-depressants; anti-diarrhea preparations; anti-histamines; anti-hypertensive drugs; anti-infectives;
anti-inflammatory agents; anti-lipid agents; anti-manics;
anti-nauseants; anti-stroke agents; anti-thyroid preparations; anti-tumor drugs; anti-tussives; anti-uricemic drugs; anti-viral agents; acne drugs; alkaloids;
amino acid preparations; anabolic drugs; analgesics;
anesthetics; angiogenesis inhibitors; antacids;
antiarthritics; antibiotics; anticoagulants; antiemetics;
antiobesity drugs; antiparasitics; antipsychotics;
antipyretics; antispasmodics; antithrombotic drugs;
anxiolytic agents; appetite stimulants; appetite suppressants; beta blocking agents; bronchodilators;
cardiovascular agents; cerebral dilators; chelating - agents; cholecystokinin antagonists; chemotherapeutic agents; cognition activators; contraceptives; coronary dilators; cough suppressants; decongestants; deodorants;
dermatological agents; diabetes agents; diuretics;
emollients; enzymes; erythropoietic drugs; expectorants;
fertility agents; fungicides; gastro-intestinal agents;
WO 1~3/241~;4 ~ r ~ . ~ c 1~CI'/US93/05307 growth regulators; hormone replacement agents;
hyperglycemic agents; hypnotics; hypoglycemic agents;
laxatives; migrain treatments; mineral supplements;
mucolytics; narcotics; neuroleptics; neuromuscular drugs;
5 ~ATn~; nutritional additives; peripheral vaso-dilators;
polypeptides; prostaglA~i nc; psychotropics; renin inhibitors; respiratory stimulants; steroids; stimulants;
sympatholytics; thyroid preparations; tranquilizers;
uterine relaxants; vaginal preparations; vaso-constrictors; vaso-dilators; vertigo agents; vitamins;
wound healing agents.
Non-limiting examples of specific bio-effecting agents which may be useful in the present invention can be chosen from the list which follows; Mixtures of these 15 agents and their salts used for appropriate therapies are also contemplated:
acetaminophen; acetic acid; acetylsalicylic acid and its buffered form; albuterol and its sulfate; alcohol;
alkaline phosphatase; allantoin; aloe; aluminum acetate, 20 carbonate, chlorohydrate, hydroxide; alprozolam; amino acids; aminobenzoic acid; amoxicillin; ampicillin;
amsacrine; amsalog; anethole; ascorbic acid; aspartame;
atenolol; bacitracin; balsam peru; BCNU (carmustine) beclomethasone dipropionate; benzocaine; benzoic acid;
25 benzophenones; benzoyl peroxide; bethanechol; biotin;
bisacodyl; bornyl acetate; bromopheniramine maleate;
buspirone; caffeine; calamine; calcium, calcium carbonate, casinate and hydroxide; camphor; captopril;
cA~cAra sagrada; castor oil; cefaclor; cefadroxil;
c~ph~lexin; cetylalcohol; cetylpyridinium chloride;
chelated minerals; chloramphenicol; chlorcyclizine hydrochloride; chlorhexidine gluconate; chloroxylenol;
chloropentostatin; chlorpheniramine maleate;
cholestyramine resin; choline bitartrate; chondrogenic stimulating protein; cimetidine hydrochloride;
cinnamedrine hydrochloride: citalopram; citric acid;
2~37268 ~
W O 93/24154 ~ r ~; ? ~ ; PC~r/US93/05307 cocoa butter; cod liver oil: codeine and codeine phosphate; clonidine and its hydrochloride salt;
clorfibrate; cortisone acetate; ciprofloxacin HC1;
cyanocobalamin; cyclizine hydrochloride; danthron;
dexbromphen;ranime maleate; dextromethorphan hydrobromide; diazapam; dibucaine; diclofenac sodium;
digoxin; diltiazem; dimethicone; dioxybenzone;
diphenhydramine citrate; diphenhydramine hydrochloride;
docusate calicum, potassium and sodium; doxycycline hyclate; doxylamine succinate; efaroxan; enalpril;
enoxacin; erythromycin; estropipate; ethinyl estradiol;
ephedrine; epinephrine bitartrate; erythropoietin;
eucalyptol; ferrous fumarate, gluconate and sulfate;
folic acid; fosphenytoin; 5-fluorouracil (5-FU) fluoxetine HCl; furosemide; gabapentan; gentamicin;
gemfibrozil; glipizide; glycerin; glyceryl stearate;
griseofulvin; growth hormone; guaifenesin;
hexylresorcinol; hydrochloro~hi~;de; hydrocodone bitartrate; hydrocortisone and its acetate; 8-hydroxyquinoline sulfate; ibuprofen; indomethacin;inositol; insulin; iodine; ipecac; iron; isoxicam;
ketamine; koalin; lactic acid; lanolin; lecithin;
leuprolide acetate; li~oc~ine and its hydrochloride salt;
lifinopril; liotrix; lovastatin; luteinizing hormone;
LHRH (luteinizing hormone releasing hormone); magnesium carbonate, hydroxide, salicylate, trisilocate; mefenamic acid; meclofenanic acid; meclofenamate sodium;
medroxyprogesterone acetate; methenamine mandelate;
menthol; meperidine hydrochloride; metaproterenol sulfate; methyl nicotinate; methyl salicylate;
methylcellulose; methsuximide; metronidazole and its - hydrochloride; metoprolol tartrate; miconazole nitrate;
mineral oil; minoxidil; morphine; naproxen and its sodium salt; nifedipine; neomycin sulfate; niacin; niacinamide;
nicotine; nicotinamide; nitroglycerin; no~o~ynol-9;
noreth;n~one and its acetate; nystatin; octoxynol;
octoxynol 9; octyl dimethyl PABA; octyl methoxycinnamate;
r ~
W O 93/24154 2 ~ 3 ~ 8 PC~r/US93/05307 omega-3 polyunsaturated fatty acids; omeprazole; oxolinic acid; oxybenzone; oxtriphylline; para-aminobenzoic acid (PABA); padimate O; paramethadione; pentastatin;
peppermint oil; pentaerythriol tetranitrate;
pentobarbital sodium; rhe~; ramine maleate; phenobarbital;
phenol; phenolphthalein; phenylephrine hydrochloride;
phenylpropanolamine and its hydrochloride salt;
phenytoin; phenelzine sulfate; pirmenol; piroxicam;
polymycin B sulfate; potassium chloride and nitrate;
prazepam; proc~inAmide hydrochloride; procaterol;
propoxyphene and its HCl salt; propoxyphene napsylate;
pramiracetin; pramoxine and its hydrochloride salt;
propronolol HCl; pseudoephedrine hydrochloride and sulfate; pyridoxine; quinapril; quinidine gluconate and sulfate; quinestrol; ralitoline; ranitadine; resorcinol;
riboflavin; salicylic acid; sesame oil; shark liver oil;
simethicone; sodium bicarbonate, citrate and fluoride;
sodium monofluorophosphate; sucralfate; sulfanethoxazole;
sulfasalazine; sulfur; tacrine and its HCl salt;
theophylline; terfenidine; thioperidone; trimethrexate;
triazolam; timolol maleate; tretinoin; tetracycline hydrochloride; tolmetin; tolnaftate; triclosan;
triprolidine hydrochloride; undecylenic acid; vancomycin;
verapamil HCl; vidaribine phosphate; vitamins A, B, C, D, B1, B2, B6, B12, E, K; witch hazel; xylometazoline hydrochloride; zinc; zinc sulfate; zinc undecylenate.
Drugs which are chemically linked to the polymer, e.g. macromolecular prodrugs are contemplated.
Useful dosage forms include without limitation oral forms such as tablets, capsules, beads, granules, aggregates, syrups, powders, gels, solids, semi-solids, suspensions and liquids. Injectable forms, lotions, transdermal delivery systems including dermal patches, implantable forms or devices, aerosols or nasal mists, suppositories, salves and ointments are also useful.
Z13~7268 WO93/~154 ; ~ i PCT/US93/05307 The inventive compositions have great versatility in their application. Of particular utility however, is the administration of bio-effecting agent to site-specific localities. For example, the controlled release compositions of the present invention can be used as the suture or component of a suture, i.e. threads of a multi-filament ~Lu~e, for wounds. There compositions can be used in steri-strip wound closure materials such as dressings and the like. The compositions can be used for wound management such as by direct application to burns, abrasions, skin diseases or infections and the like.
Other uses such as packing agents for nasal wounds or other open wounds are also contemplated. The packing agents can, for example, also contain blood clotting factors such as proconvertin, plasma thromboplastin, Stuart factor, Vitamin K, fibrinogen, drugs such as phytonadione or hormones such as estrogen.
In certain preferred embodiments, a growth regulator, such as a human somatatropin, a bovine somatatropin or a porcine somatatropin, is incorporated in the non-saccharide polymer. The biodegradable polymers which are melt-spun together with human somatotropin can be effectively used in tissue cultures to promote growth of human tissue. The growth of cells from fetal tissue or foreskin tissue can be stimulated by the gradual release of the hormone from the biodegradable polymer. The biodegradable polymer contA i n ing the growth hormone can be in the form of fibers or it can be material obtained by placing a support close to the spinning head to collect the material on the support - while it is still in its flowable state. Where a support is coated with such biodegradable polymer containing the hormone, the cells to be grown can be placed over the coated support to form tissue segments or patches which can be used for skin grafts and the like. Cartilage tissues can also be grown by similar procedures.
WO93/~154 2~ 8~ PCT/US93/05307 In applications involving treatment of ruminants, if the dosage form is to be administered orally, the polymer must provide a protective barrier against the fluids of the rumen and allow for passage to the abomasum where polymeric degradation and concomitant release of active can occur over time. This generally means that the polymeric matrix or carrier is designed to be resistant to pH>5 but slowly degraded at pH<3.5.
In the case of oral administration of actives, such as insulin, which are destroyed in gastric juices, the polymer must provide a similar protective and delivery function. Of course, alternatives to oral a~ ;stration include biodegradable implants which are designed to deliver the appropriate therapeutic dose for the specific condition treated.
A variety of additives can be incorporated into the inventive compositions for their inten~ functions.
Their additives are generally added in minor amounts.
Examples of classes of additives include excipients, lubricants, buffering agents, disintegrating agents, stabilizers, foaming agents, pigments, coloring agents, fillers, bulking agents, sweetening agents, flavoring agents, fragrances, release modifiers, adjuvants, plasticizers, flow accelerators, polyols, granulating agents, diluents, binders, buffers, absorbents, glidants, adhesives, antiadherents, acidulants, softeners, resins, demulcents, solvents, surfactants, emulsifiers, elastomers and mixtures thereof.
Useful additives include, for example, gelatin, vegetable proteins such as sunflower protein, soybean proteins r cotton seed proteins, peanut proteins, rape seed proteins, blood proteins, egg proteins, acrylated proteins; water-soluble polysaccharides such as alginates, carrag~enAn~ guar gum, agar-agar, gum arabic 2~37Z6~
W O 93/24154 ' `- PC~r/US93/05307 and related gums (gum ghatti, gum karaya, gum tragacanth), pectin; water-soluble derivatives of cellulose: alkylcelluloses, hydroxyalkylcelluloses and hydroxyalkylalkylcelluloses, such as methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxpropylmethylcellulose, hydloxL~Lylmethylcellulose, cellulose esters and hydroxyalkylcellulose esters such as: cellulose acetate phthalate (CAP), carboxyalkylcelluloses, carboxyalkylalkylcelluloses, carboxyalkylcellulose esters such as carboxymethylcellulose and their alkali metal salts;
water-soluble synthetic polymers such as polyacrylic acids and polyacrylic acid esters, polymethacrylic acids and polymethacrylic acid esters, polyvinylacetates, polyvinylalcohols, polyvinylacetatephthalates (PVAP), polyvinylpyrrolidone (PVP), PVP/vinyl acetate copolymer, and polycrotonic acids; also suitable are phthalated gelatin, gelatin succinate, crosslinked gelatin, shellac, water-soluble chemical derivatives of starch, cationically modified acrylates and methacrylates possessing, for example, a tertiary or guaternary amino group, such as the diethylaminoethyl group, which may be quaternized if desired; and other similar polymers.
Processing aids such as mono- and triglycerides are useful as well. In certain preferred embodiments, saccharides such as sucrose, maltodextrin, polydextrose, lactose, maltose and the like are added to the non-saccharide polymer in amounts of about 1 to about 35% by weight of the non-saccharide polymer. The bioeffecting - agent is mixed with the saccharide before spinning and in certain embodiments can be present in both the saccharide material and the non-saccharide carrier. Upon sp; nn; ng, the saccharide tends to form pockets or cavities within the non-saccharide polymer which results in a material where the bioeffecting agent is released in accordance WO93/~1~ 2~372~8 PCT/US93/05307 0 with diffusion gradients from the relatively soluble saccharides and in accordance with the degradation properties of the non-saccharide polymer when the bioactive compound is incorporated in such polymer.
Further additives may be inorganic fillers, such as the oxides of magnesium, aluminum, silicon, titanium, and the like preferably in a concentration range of about 0.02 to about 3% by weight and preferably about 0.02 to about 1% based on the weight of all components.
Further examples of additives are plasticizers which include polyalkylene oxides, such as polyethylene glycols, polypropylene glycols, polyethylene-propylene glycols; organic plasticizers with lcw molecular weights, such as glycerol, glycerol monoacetate, diacetate or triacetate; propylene glycol, sorbitol, sodium diethylsulfosuccinate, triethyl citrate, tributyl citrate, and the like.
Examples of coloring agents include known azo dyes, organic or inorganic pigments, or coloring agents of natural origin. Inorganic pigments are preferred, such as the oxides of iron or titanium.
one particularly useful class of additives which can be incorporated into the spun matrix of the present compositions include radio opaque materials. These materials can be used to monitor the position of the controlled release composition via x-rays, and in cases where non-biodegradable material is present, such as carbon fibers, these will remain in the body subsequent to degradation of the polymer as a marker to show the site of the wound of the cite of treatment.
Prior to forming the polymer and drug mixture, the polymers were cryG~Lou~.d to reduce the particle size and WO93/241~ 2137~8 PCT/US93/05307 facilitate spinning. Cryogrinding was conducted under liquid nitrogen in a RETSCH Model ZM-1 Ultra Centrifugal Mill, 2.0 mm sieve with 12 tooth rotor.
The amount of bio-effecting active present is dependent upon the treatment indicated. The bio-effecting/polymer ratios will vary accordingly. In general, however, the polymer is present in amounts of about 50 to 99% by weight and preferably about 75 to 90%.
The balance of the composition is active, with various amounts of additives as previously mentioned.
F~AMpLEs Four biodegradable polymers were melt-spun in combination with various drugs to sl~cc~ssfully make compositions useful in the present invention. The polymers used were (1) polyglycolide, a copolymer of L(-) lactide (69.29%) and glycolide (30.05%), (2) p-dioxane, (3) polycaprolactone and (4) polysabacic acid. These polymers were used to encapsulate the drugs vancomycin, gentamicin, tolmetin, diphenhydramine, ibuprofen and insulin, as shown in Table I below.
Each composition was formed by first mixing the drug and a processing aid (medium chain triglyceride supplied by Huls America under the name Miglycol 812) in a mortar and pestle. The biodegradable polymer was then slowly added with continuous mixing. The mixtures were preferably homogeneous.
Each of the example mixtures were spun on an Econo Floss spinning machine which was modified to provide for variable temperature of the heating ribbon and variable speed of the rotating head. The spinning head was 5.5 inches in diameter having slits in the outer containment band which were 3-5mm long by 0.5-0.75mm wide. Where a WO93~ 3~6~ PCr/US93/05307 Kapton0 liner is specified, it is a band of Kapton polymer (polyimide available from DuPont) material inserted between the heating element and the outer containment band with 0.042" holes in the Kapton~ band aligned with the slots in the outer containment band.
Table I also indicates the relative weight percents of the melt-spun components as well as the rotational speed (RPM) and temperature of the spinning head.
4 Z~3t7~8 PCI~/US93/05307 * 27 *
C s~
o o lY o o o o W lY o o o o o Z Z :~ Z Z Z Z ~ ~ Z Z Z Z Z
o O O O O O O O O o o o u) In In ~
o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o .
;G ;~ a~
3~ x ~
* ~ V ~ U
* ~ ~ X ~ x ~ x x ~ x a E- o <~ p V C~
a a c ~P ~ C C C CO C s~ _ ~ ~ ~ ~ ~ ~ ~
, v ~ ~, _ a~ o ~ ~ :~
~ ~ ~ a ~ o t) o o o ~ o o o ~ a a o a c ~ -- -- v --~
* ~ ~ ~ -- ~ P~ ~ U -- ~ P~
dP
~1 a~ ~~1 ~ ~ ~P ~ r- r~ o o Z ~Z ~ Z
o a) ~ s~ a~ o ~ ~ a~ ~ o ~ o t) ~ o a) S2 ,i ~ o a~ o P E~ ~ H a P E~ ~ E~ ~ P H H P C
X O ~1 ., " . ¦; r i W093/241~ PCT/US93/05307 * Copolymer of L(-) lactide (69.29%) and glycolide (30.05%) ** MCT = medium chain triglyceride (miglycol 812, Huls America) *** Kapton liner with three 0.042" holes per containment band slot (a) PDS = poly-para-dioxane polymer (b) P(SA) = polysabacic acid polymer (c) P(CPL) = polycaprolactone polymer (d) MW 40-lOOM (Medisorb lOODL available from Medisorb International L.P.) (e) MW lOOM+ (Medisorb lOOL available from Medisorb International L.P.) In Example l, the sample was exposed to 2.7 MRAD/Co 60 for sterilization and then assayed using HPLC for the amount of Vancomycin present. The actual assayed amount (ll.26%) substantially matches the theoretical amount (11%) indicating that all of the drug was encapsulated or carried through the melt-spin process with the polymer without apparent degradation.
The rate of release of Vancomycin from the polymer was then determined through an in vitro extraction study using the following method. The release rates are tabulated in Table II and graphically represented in Figures l and 2.
A sample of the vancomycin melt-spun polymer product (.5g) is placed in the flow unit between filter disks (.22 um Millipore GV) and maintained at 25-C. Krebs-Ringer buffer (Ph 7.4, Sigma Chemical) was pumped from a refrigerated reservoir (5C). The solution was warmed at 25~C before flowing through a filter unit (Millipore Swinnex-47) at a flow rate of 2 ml/h. An initial sample (60 Ml) was taken at an accelerated flow rate (30 Ml/min.). Fractions were collected (ISCO-Foxy 200) every Z~3t7268 WO93/~1~ PCT/US93/05307 24 h and frozen. After 7 days, the fractions are analyzed for vancomycin content. The experiment was continued for an additional 7 days and the remaining~ ;
polymer was removed from the filter unit, rinsed, dried weighed and the vancomycin content calculated. The results are tabulated below and graphically illustrated in Figures 1 and 2.
TABLE II
VANCOMYCIN ELUTED (mg) Elapsed Time (DaYs)Sample #1 Sample #2 o1 1.50 4.66 1 7.56 6.85 2 2.49 1.82 3 0.65 0.44 4 0.49 0.21 0.08 0.30 6 0.15 0.15 7 0.13 0.14 8 0.06 0.05 9 0.06 0.04 0.08 0.07 11 0.11 0.07 12 0.09 0.06 13 0.07 0.07 14 0.07 0.06 Eluted Vancomycin:13.57mg 14.99mg Remaining: 2 4.08mg 4.08mg Total: 17.65mg 19.07mg Initial Sample wt:200.26mg 200.27mg 1From initial 60 Ml flush.
2Vancomycin which r~ine~ in the dried polymer at the end of two weeks.
~ s 2137268 '` ` ' PCI~/US93/05307 --HPLC analysis of fractions was performed using a Beckman System Gold system (Model 126 Pump and Model 166 W Detector). The column used was a Phenomenex Ultracarb 5u C8 column. The mobil phase composition was comprised of water (81%), acetonitrile (9%) and .2M ammonium acetate (10%). W detection (A=214 nm) was employed.
The flow rate was .8 ml/min. St~n~rd solutions were prepared daily (10, 20 and 30 ug/ml) each time HPLC
analysis was performed. All HPLC injections were done in lo duplicate.
The results demonstrate that a higher concentration of vancomycin was eluted in the first few days of the experiment. The release rate appeared to taper off after 3-4 days. After two days, the amount of vancomycin released per day drops. After six days, vancomycin release begins to level out between 60 and 100 ug. The vancomycin polymer was originally 13.5% vancomycin by weight. After two weeks, the polymer samples were assayed for vancomycin content. Both samples were found to contain 4.08mg vancomycin which represents 15.1% of the total vancomycin present. 65% of Sample 1 was accounted for while 70% of Sample 2 was recovered. This loss of approximately 30% of the total vancomycin is believed to be due to degradation of the vancomycin over time, when exposed to 5C in the fraction collector.
In Examples 2-8, 10, 14 and 15 the melt-spun controlled release product demonstrated successful combination of active (drug) and biodegradable product.
In Example 9, the melt-spun product was assayed for gentamicin and it was determined that 89.9% of the theoretical content was present.
Example 11 indicates that the polymer can be melt-spun without the addition of an active and without a Kapton liner.
~ WO93~154 2~37Z68 ~PCT/US93/05307 i ~ .
31 ~ -~
Example 12 and 13, the presence of insulin in the melt-spun product was confirmed by radioimmunoassay (RIA)-Thus, while there have been disclosed what are presently believed to be the preferred embodiments of thepresent invention, other and further manifestations of the invention will become apparent to those skilled in the art. It is intended to claim all such changes and modifications which come within the true scope and spirit of the present invention.
C s~
o o lY o o o o W lY o o o o o Z Z :~ Z Z Z Z ~ ~ Z Z Z Z Z
o O O O O O O O O o o o u) In In ~
o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o .
;G ;~ a~
3~ x ~
* ~ V ~ U
* ~ ~ X ~ x ~ x x ~ x a E- o <~ p V C~
a a c ~P ~ C C C CO C s~ _ ~ ~ ~ ~ ~ ~ ~
, v ~ ~, _ a~ o ~ ~ :~
~ ~ ~ a ~ o t) o o o ~ o o o ~ a a o a c ~ -- -- v --~
* ~ ~ ~ -- ~ P~ ~ U -- ~ P~
dP
~1 a~ ~~1 ~ ~ ~P ~ r- r~ o o Z ~Z ~ Z
o a) ~ s~ a~ o ~ ~ a~ ~ o ~ o t) ~ o a) S2 ,i ~ o a~ o P E~ ~ H a P E~ ~ E~ ~ P H H P C
X O ~1 ., " . ¦; r i W093/241~ PCT/US93/05307 * Copolymer of L(-) lactide (69.29%) and glycolide (30.05%) ** MCT = medium chain triglyceride (miglycol 812, Huls America) *** Kapton liner with three 0.042" holes per containment band slot (a) PDS = poly-para-dioxane polymer (b) P(SA) = polysabacic acid polymer (c) P(CPL) = polycaprolactone polymer (d) MW 40-lOOM (Medisorb lOODL available from Medisorb International L.P.) (e) MW lOOM+ (Medisorb lOOL available from Medisorb International L.P.) In Example l, the sample was exposed to 2.7 MRAD/Co 60 for sterilization and then assayed using HPLC for the amount of Vancomycin present. The actual assayed amount (ll.26%) substantially matches the theoretical amount (11%) indicating that all of the drug was encapsulated or carried through the melt-spin process with the polymer without apparent degradation.
The rate of release of Vancomycin from the polymer was then determined through an in vitro extraction study using the following method. The release rates are tabulated in Table II and graphically represented in Figures l and 2.
A sample of the vancomycin melt-spun polymer product (.5g) is placed in the flow unit between filter disks (.22 um Millipore GV) and maintained at 25-C. Krebs-Ringer buffer (Ph 7.4, Sigma Chemical) was pumped from a refrigerated reservoir (5C). The solution was warmed at 25~C before flowing through a filter unit (Millipore Swinnex-47) at a flow rate of 2 ml/h. An initial sample (60 Ml) was taken at an accelerated flow rate (30 Ml/min.). Fractions were collected (ISCO-Foxy 200) every Z~3t7268 WO93/~1~ PCT/US93/05307 24 h and frozen. After 7 days, the fractions are analyzed for vancomycin content. The experiment was continued for an additional 7 days and the remaining~ ;
polymer was removed from the filter unit, rinsed, dried weighed and the vancomycin content calculated. The results are tabulated below and graphically illustrated in Figures 1 and 2.
TABLE II
VANCOMYCIN ELUTED (mg) Elapsed Time (DaYs)Sample #1 Sample #2 o1 1.50 4.66 1 7.56 6.85 2 2.49 1.82 3 0.65 0.44 4 0.49 0.21 0.08 0.30 6 0.15 0.15 7 0.13 0.14 8 0.06 0.05 9 0.06 0.04 0.08 0.07 11 0.11 0.07 12 0.09 0.06 13 0.07 0.07 14 0.07 0.06 Eluted Vancomycin:13.57mg 14.99mg Remaining: 2 4.08mg 4.08mg Total: 17.65mg 19.07mg Initial Sample wt:200.26mg 200.27mg 1From initial 60 Ml flush.
2Vancomycin which r~ine~ in the dried polymer at the end of two weeks.
~ s 2137268 '` ` ' PCI~/US93/05307 --HPLC analysis of fractions was performed using a Beckman System Gold system (Model 126 Pump and Model 166 W Detector). The column used was a Phenomenex Ultracarb 5u C8 column. The mobil phase composition was comprised of water (81%), acetonitrile (9%) and .2M ammonium acetate (10%). W detection (A=214 nm) was employed.
The flow rate was .8 ml/min. St~n~rd solutions were prepared daily (10, 20 and 30 ug/ml) each time HPLC
analysis was performed. All HPLC injections were done in lo duplicate.
The results demonstrate that a higher concentration of vancomycin was eluted in the first few days of the experiment. The release rate appeared to taper off after 3-4 days. After two days, the amount of vancomycin released per day drops. After six days, vancomycin release begins to level out between 60 and 100 ug. The vancomycin polymer was originally 13.5% vancomycin by weight. After two weeks, the polymer samples were assayed for vancomycin content. Both samples were found to contain 4.08mg vancomycin which represents 15.1% of the total vancomycin present. 65% of Sample 1 was accounted for while 70% of Sample 2 was recovered. This loss of approximately 30% of the total vancomycin is believed to be due to degradation of the vancomycin over time, when exposed to 5C in the fraction collector.
In Examples 2-8, 10, 14 and 15 the melt-spun controlled release product demonstrated successful combination of active (drug) and biodegradable product.
In Example 9, the melt-spun product was assayed for gentamicin and it was determined that 89.9% of the theoretical content was present.
Example 11 indicates that the polymer can be melt-spun without the addition of an active and without a Kapton liner.
~ WO93~154 2~37Z68 ~PCT/US93/05307 i ~ .
31 ~ -~
Example 12 and 13, the presence of insulin in the melt-spun product was confirmed by radioimmunoassay (RIA)-Thus, while there have been disclosed what are presently believed to be the preferred embodiments of thepresent invention, other and further manifestations of the invention will become apparent to those skilled in the art. It is intended to claim all such changes and modifications which come within the true scope and spirit of the present invention.
Claims (26)
1. A biodegradable controlled release composition formed by flash-flow melt-spinning comprising a non-saccharide biodegradable polymer and a bio-effecting agent.
2. The composition of Claim 1, wherein the polymer is selected from the group consisting of: poly(glycolic acid), poly(lactic acid), polydioxanes, polyoxalates, poly(.alpha.-esters), polycarbonates, polyanhydrides, polyacetals, polycaprolactones, poly(orthoesters), polyamino acids, polyurethane, polyiminocarbonates, polyamides, poly(alkyl cyanoacrylates), sebacic acid, polyethylene glycol, polyphosphazene, bis(p-carboxyphenoxy)propane, bis(p-carboxyphenoxy)methane and copolymers and mixtures thereof.
3. The composition of Claim 2, wherein the bio-effecting agent is useful in the prophylactic or therapeutic treatment of an animal.
4. The composition of Claim 3, wherein the bio-effecting agent is selected from the group consisting of ace-inhibitors, anti-asthmatics, anti-cholesterolemics, anti-convulsants, anti-depressants, anti-diarrhea preparations, anti-infectives, anti-inflammatory agents, anti-nauseants, anti-stroke agents, anti-thyroid preparations, anti-tumor drugs, anti-tussives, anti-uricemic drugs, acne drugs, alkaloids, amino-acid preparations, anabolic drugs, antiemetics, antiobesity drugs, anti-parasitics, antipyretics, anti-spasmodics, appetite stimulants, cerebral dialators, chelating agents, cholecystokinin antagonists, cognition activators, contraceptives, deodorants, dermatological agents, diabetes agents, diuretics, erythropoietic drugs, fertility agents, synthetic hormone replacement agents, hyperglycemic agents, laxatives, mineral supplements, neuroleptics, neuromuscular agents, peripheral vaso-dilators, prostaglandins, vaginal preparations, vaso-constrictors and vertigo agents.
5. The composition of Claim 4, wherein the bio-effecting agent is selected from the group consisting of acetaminophen, acetic acid, acetylsalicylic acid, buffered acetylsalicylic acid, albuterol, albuterol sulfate, ethanol, isopropanol, allantoin, aloe, aluminum acetate, aluminum carbonate, aluminum chlorohydrate, aluminum hydroxide, alprozolam, amino acids, aminobenzoic acid, amoxicillin, ampicillin, amsacrine, amsalog, anethole, aspartame, atenolol, bacitracin, balsam peru, beclomethasone dipropionate, benzocaine, benzoic acid, benzophenones, benzoyl peroxide, biotin, bisacodyl, bornyl acetate, bromopheniramine maleate, buspirone, caffeine, calamine, calcium, calcium carbonate, calcium casinate, calcium hydroxide, camphor, captopril, cascara sagrada, castor oil, cefaclor, cefadroxil, cephalexin, cetylalcohol, cetylpyridinium chloride, chelated minerals, chloramphenicol, chlorcyclizine hydrochloride, chlorhexidine gluconate, chloroxylenol, chloropentostatin, chlorpheniramine maleate, cholestyramine resin, choline bitartrate, cimetidine hydrochloride, cinnamedrine hydrochloride, citalopram, citric acid, cocoa butter, cod liver oil, codeine and codeine phosphate, clonidine, clonidine hydrochloride, clorfibrate, ciprofloxacin HCl, cyanocobalamin, cyclizine hydrochloride, danthron, dexbrompheniranime maleate, dextromethorphan hydrobromide, diazapam, dibucaine, diclofenac sodium, digoxin, diltiazem, dimethicone, dioxybenzone, diphenhydramine citrate, diphenhydramine hydrochloride, docusate calicum, docusate potassium, docusate sodium, doxycycline hyclate, doxylamine succinate, efaroxan, enalpril, enoxacin, erythromycin, estropipate, ethinyl estradiol, ephedrine, epinephrine bitartrate, erythropoietin, eucalyptol, ferrous fumarate, ferrous gluconate, ferrous sulfate, folic acid, fosphenytoin, fluoxetine HCl, furosemide, gabapentan, gentamicin, gemfibrozil, glipizide, glycerin, glyceryl stearate, griseofulvin, guaifenesin, hexylresorcinol, hydrochlorothiaxide, hydrocodone bitartrate, hydrocortisone, hydrocoritisone acetate, 8-hydroxyquinoline sulfate, ibuprofen, indomethacin, inositol, insulin, iodine, ipecac, iron, isoxicam, ketamine, koalin, lactic acid, lanolin, lecithin, lidocaine, lidocaine hydrochloride, lifinopril, liotrix, lovastatin, magnesium carbonate, magnesium hydroxide, magnesium salicylate, magnesium trisilocate, mefenamic acid, meclofenanic acid, meclofenamate sodium, medroxyprogesterone acetate, methenamine mandelate, menthol, meperidine hydrochloride, metaproterenol sulfate, methyl nicotinate, methyl salicylate, methylcellulose, methsuximide, metromidazole, metromidazole hydrochloride, metoprolol tartrate, miconazole nitrate, mineral oil, minoxidil, morphine, naproxen, naproxen sodium, nifedipine, neomycin sulfate, niacin, niacinamide, nicotine, nicotinamide, nitroglycerin, nonoxynol-9, norethindone, norethindone acetate, nystatin, octoxynol, octoxynol 9, octyl dimethyl PABA, octyl methoxycinnamate, omega-3 polyunsaturated fatty acids, omeprazole, oxolinic acid, oxybenzone, oxtriphylline, para-aminobenzoic acid (PABA), padimate 0, paramethadione, pentastatin, peppermint oil, pentaerythriol tetranitrate, pentobarbital sodium, pheniramine maleate, phenobarbital, phenol, phenolphthalein, phenylephrine hydrochloride, phenylpropanolamine, phenylpropanolamine hydrochloride, phenytoin, phenelzine sulfate, pirmenol, piroxicam, polymycin B sulfate, potassium chloride, potassium nitrate, prazepam, procainamide hydrochloride, procaterol, propoxyphene, propoxyphene HCl, propoxyphene napsylate, pramiracetin, pramoxine, pramoxine hydrochloride, propronolol HCl, pseudoephedrine hydrochloride, pseudoephedrine sulfate, pyridoxine, quinapril, quinidine qluconate, quinestrol, ralitoline, ranitadine, resorcinol, riboflavin, salicylic acid, sesame oil, shark liver oil, simethicone, sodium bicarbonate, sodium citrate, sodium fluoride, sodium monofluorophosphate, sulfanethoxazole, sulfur, tacrine, tacrine HCl, theophylline, terfenidine, thioperidone, trimethrexate, triazolam, timolol maleate, tretinoin, tetracycline hydrochloride, tolmetin, tolnaftate, triclosan, triprolidine hydrochloride, undecylenic acid, vancomycin, verapamil HCl, vidaribine phosphate, vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, witch hazel, xylometazoline hydrochloride, zinc, zinc sulfate, and zinc undecylenate.
6. The composition of Claim 3 in an oral dosage form.
7. The composition of Claim 3 in an implantable dosage form.
8. The composition of Claim 3 useful in a wound treatment dosage form.
9. A controlled release melt-spun composition comprising:
(a) a non-saccharide biodegradable polymer capable of physically protecting an active agent past the stomach and releasing the active agent in the small intestine; and (b) a bio-effecting agent.
(a) a non-saccharide biodegradable polymer capable of physically protecting an active agent past the stomach and releasing the active agent in the small intestine; and (b) a bio-effecting agent.
10. The composition of Claim 9, wherein the polymer is selected from the group consisting of: poly(glycolic acid), poly(lactic acid), polydioxanes, polyoxalates, poly(.alpha.-esters), polycarbonates, polyanhydrides, polyacetals, polycaprolactones, poly(orthoesters), polyamino acids, polyurethanes, polyiminocarbonates, polyamides, poly(alkyl cyanoacrylates), sebacic acid, polyethylene glycol, polyphosphazene, bis(p-carboxyphenoxy)propane, bis(p-carboxyphenoxy)methane, and copolymers and mixtures thereof.
11. The composition of Claim 9, wherein the bio-effecting agent is selected from the group consisting of peptides, antibiotics, hormones, growth regulators and mixtures thereof.
12. The composition of Claim 11, wherein the bio-effecting agent is insulin.
13. A controlled release flash-flow melt-spun composition for treatment of ruminants comprising: a) a non-saccharide biodegradable polymer which is protective of an active in the environment of the rumen at pH of about 5 or more but which releases the active in environment of the abomasum at pH of about 3.5 or less:
and b) a bio-effecting active.
and b) a bio-effecting active.
14. The composition of Claim 13, wherein the active is a therapeutic, prophylactic or nutritive agent.
15. The composition of Claim 13, wherein the active is selected from the group consisting of antibiotics, antiparasitics, amino-acids, proteins, growth regulators, hormones and mixtures thereof.
16. A method of treating an animal comprising administering to said animal an effective amount of a melt-spun controlled release composition comprising a non-saccharide biodegradable polymer and a bio-effecting therapeutic or prophylactive active.
17. The method of Claim 16, wherein the polymer is selected from the group consisting of: poly(glycolic acid), poly(lactic acid), polydioxanes, polyoxalates, poly(.alpha.-esters), polycarbonates, polyanhydrides, polyacetals, polycaprolactones, poly(orthoesters), polyamino acids, polyurethanes, polyiminocarbonates, polyamides, poly(alkyl cyanoscrylates), sebacic acid, polyethylene glycol, polyphosphazene, bis(p-carboxyphenoxy)propane, bis(p-carboxyphenoxy)methane and copolymers and mixtures thereof.
18. The composition of Claim 16, wherein the bio-effecting agent is selected from the group consisting of acetaminophen, acetic acid, acetylsalicylic acid and its buffered form, albuterol, and albuterol sulfate, ethanol isopropanol, allantoin, aloe, aluminum acetate, aluminum carbonate, chlorohydrate, hydroxide, alprozolam, amino acids, aminobenzoic acid, amoxicillin, ampicillin, amsacrine, amsalog, anethole, aspartame, atenolol, bacitracin, balsam peru, beclomethasone dipropionate, benzocaine, benzoic acid, benzophenones, benzoyl peroxide, biotin, bisacodyl, bornyl acetate, bromopheniramine maleate, buspirone, caffeine, calamine, calcium, calcium carbonate, calcium casinate, calcium hydroxide, camphor, captopril, cascara sagrada, castor oil, cefaclor, cefadroxil, cephalexin, cetylalcohol, cetylpyridinium chloride, chelated minerals, chloramphenicol, chlorcyclizine hydrochloride, chlorhexidine gluconate, chloroxylenol, chloropentostatin, chlorpheniramine maleate, cholestyramine resin, choline bitartrate, cimetidine hydrochloride, cinnamedrine hydrochloride, citalopram, citric acid, cocoa butter, cod liver oil, codeine and codeine phosphate, clonidine, clonidine hydrochloride, clorfibrate, ciprofloxacin HCl, cyanocobalamin, cyclizine hydrochloride, danthron, dexbrompheniranime maleate, dextromethorphan hydrobromide, diazapam, dibucaine, diclofenac sodium, digoxin, diltiazem, dimethicone, dioxybenzone, diphenhydramine citrate, diphenhydramine hydrochloride, docusate calicum, docusate potassium, docusate sodium, doxycycline hyclate, doxylamine succinate, efaroxan, enalpril, enoxacin, erythromycin, estropipate, ethinyl estradiol, ephedrine, epinephrine bitartrate, erythropoietin, eucalyptol, ferrous fumarate, ferrous gluconate, ferrous sulfate, folic acid, fosphenytoin, fluoxetine HCl, furosemide, gabapentan, gentamicin, gemfibrozil, glipizide, glycerin, glyceryl stearate, griseofulvin, guaifenesin, hexylresorcinol, hydrochlorothiaxide, hydrocodone bitartrate, hydrocortisone, hydrocoritisone acetate, 8-hydroxyquinoline sulfate, ibuprofen, indomethacin, inositol, insulin, iodine, ipecac, iron, isoxicam, ketamine, koalin, lactic acid, lanolin, lecithin, lidocaine, lidocaine hydrochloride, lifinopril, liotrix, lovastatin, magnesium carbonate, magnesium hydroxide, salicylate, magnesium trisilocate, mefenamic acid, meclofenanic acid, meclofenamate sodium, medroxyprogesterone acetate, methenamine mandelate, menthol, meperidine hydrochloride, metaproterenol sulfate, methyl nicotinate, methyl salicylate, methylcellulose, methsuximide, metromidazole, metromidazole hydrochloride, metoprolol tartrate, miconazole nitrate, mineral oil, minoxidil, morphine, naproxen, naproxen sodium, nifedipine, neomycin sulfate, niacin, niacinamide, nicotine, nicotinamide, nitroglycerin, nonoxynol-9, norethindone, norethindone acetate, nystatin, octoxynol, octoxynol 9, octyl dimethyl PABA, octyl methoxycinnamate, omega-3 polyunsaturated fatty acids, omeprazole, oxolinic acid, oxybenzone, oxtriphylline, para-aminobenzoic acid (PABA), padimate 0, paramethadione, pentastatin, peppermint oil, pentaerythriol tetranitrate, pentobarbital sodium, pheniramine maleate, phenobarbital, phenol, phenolphthalein, phenylephrine hydrochloride, phenylpropanolamine, phenylpropanolamine hydrochloride, phenytoin, phenelzine sulfate, pirmenol, piroxicam, polymycin B sulfate, potassium chloride, potassium nitrate, prazepam, procainamide hydrochloride, procaterol, propoxyphene, propoxyphene HCl, propoxyphene napsylate, pramiracetin, pramoxine, pramoxine hydrochloride, propronolol HCl, pseudoephedrine hydrochloride, pseudoephedrine sulfate, pyridoxine, quinapril, quinidine qluconate, quinestrol, ralitoline, ranitadine, resorcinol, riboflavin, salicylic acid, sesame oil, shark liver oil, simethicone, sodium bicarbonate, sodium citrate, sodium fluoride, sodium monofluorophosphate, sulfanethoxazole, sulfur, tacrine, tacrine HCl, theophylline, terfenidine, thioperidone, trimethrexate, triazolam, timolol maleate, tretinoin, tetracycline hydrochloride, tolmetin, tolnaftate, triclosan, triprolidine hydrochloride, undecylenic acid, vancomycin, verapamil HCl, vidaribine phosphate, vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, witch hazel, xylometazoline hydrochloride, zinc, zinc sulfate, and zinc undecylenate.
19. The method of Claim 16, wherein the polymer is erodible in the presence of animal body fluids.
20. A flash-flow melt-spun drug delivery system capable of controllably releasing a pharmaceutically active agent in an animal comprising a non-saccharide biodegradable polymer and a pharmaceutically active agent wherein the polymer is in substantially amorphous form.
21. A method of preparing a controlled release pharmaceutical composition comprising subjecting a mixture of a biodegradable non-saccharide polymer and a pharmaceutically active agent to flash-flow melt-spinning to unite said polymer and active under conditions which produce a solid capable of releasing said active in an animal.
22. A device for promoting the growth of living tissue comprising a biocompatable or implantable support structure impregnated or coated with a biodegradable controlled release flash-flow melt-spun composition comprising a non-saccharide biodegradable polymer and a bio-effecting agent.
23. The device of Claim 22, wherein the bio-effecting agent is selected from the group consisting of human, bovine and porcine growth hormone.
24. A method of making a device for promoting the growth of living tissue comprising (i) flash-flow melt-spinning a composition comprising a non-saccharide biodegradable polymer and a bio-effecting agent and (ii) collecting said composition on a support structure.
25. The composition of Claim 3, wherein the bio-effecting agent is selected from the group consisting of anti-histamines, anti-manics, anti-viral agents, anesthetics, antacids, anti-arthritics, anti-biotics, anti-coagulants, anti-psychotics, anti-spasmodics, anti-thrombotic drugs, anxiolytic agents, appetite suppressants, cardiovascular agents, cough suppressants, emollients, gastro-intestinal agents, growth regulators, hypoglycemic agents, respiratory stimulants, and vitamins.
26. The method of Claim 16, wherein the bioeffecting agent is selected from the group consisting of anti-histamines, anti-manics, anti-viral agents, anesthetics, antacids, anti-arthritics, anti-biotics, anti-coagulants, anti-psychotics, anti-spasmodics, anti-thrombotic drugs, anxiolytic agents, appetite suppressants, cardiovascular agents, cough suppressants, emollients, gastro-intestinal agents, growth regulators, hypoglycemic agents, respiratory stimulants, and vitamins.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/893,238 | 1992-06-03 | ||
US07/893,238 US5518730A (en) | 1992-06-03 | 1992-06-03 | Biodegradable controlled release flash flow melt-spun delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2137268A1 true CA2137268A1 (en) | 1993-12-09 |
Family
ID=25401250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002137268A Abandoned CA2137268A1 (en) | 1992-06-03 | 1993-06-02 | Biodegradable controlled release melt-spun delivery system |
Country Status (7)
Country | Link |
---|---|
US (1) | US5518730A (en) |
EP (1) | EP0746342B1 (en) |
JP (1) | JP3941878B2 (en) |
AU (1) | AU665844B2 (en) |
CA (1) | CA2137268A1 (en) |
DE (1) | DE69332210T2 (en) |
WO (1) | WO1993024154A1 (en) |
Families Citing this family (280)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT68509A (en) * | 1991-05-17 | 1995-06-28 | Fuisz Technologies Ltd | New thermoplastic polymeric material and process for making same |
DE59302200D1 (en) * | 1992-05-22 | 1996-05-15 | Goedecke Ag | METHOD FOR PRODUCING RETARDED DRUG PREPARATIONS |
US5548064A (en) * | 1993-05-24 | 1996-08-20 | Biotech Australia Pty Limited | Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions |
US6726930B1 (en) * | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
HU212428B (en) * | 1994-05-13 | 1996-06-28 | Egyt Gyogyszervegyeszeti Gyar | Process to prepare pharmaceutical compositions containing gemfibrozyl |
US6020002A (en) * | 1994-06-14 | 2000-02-01 | Fuisz Technologies Ltd. | Delivery of controlled-release system(s) |
US5698224A (en) * | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
US5582855A (en) | 1994-07-01 | 1996-12-10 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
US6491945B1 (en) * | 1994-09-16 | 2002-12-10 | Alza Corporation | Hydrocodone therapy |
US5683720A (en) * | 1994-10-28 | 1997-11-04 | Fuisz Technologies Ltd. | Liquiflash particles and method of making same |
WO1997002019A1 (en) * | 1995-06-30 | 1997-01-23 | Baylor University | Polyester/carboxylic acid composite materials |
US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
DK0755633T3 (en) * | 1995-07-28 | 2000-04-17 | Herbert Schlachter | two-phase |
ES2112765B1 (en) * | 1995-08-02 | 1999-03-01 | Cantabria Ind Farmaceutica Sa | PROCEDURE FOR OBTAINING RADIOLOGICAL CONTRAST FORMULATIONS, FOR GASTROINTESTINAL EXPLORATIONS FOR EXTEMPORARY AND DIRECT USE. |
JPH11514979A (en) * | 1995-09-07 | 1999-12-21 | フイズ テクノロジーズ リミテッド | Bioavailable system for virtually insoluble bioactive agents |
KR0180334B1 (en) * | 1995-09-21 | 1999-03-20 | 김윤 | Drug messenger using el-2l-2 micelle and method for sealing drug to it |
US5968543A (en) * | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
SE9600070D0 (en) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
EP1616563A3 (en) * | 1996-05-24 | 2006-01-25 | Angiotech Pharmaceuticals, Inc. | Perivascular administration of anti-angiogenic factors for treating or preventing vascular diseases |
US5955096A (en) * | 1996-06-25 | 1999-09-21 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients |
US20030077317A1 (en) * | 1996-06-25 | 2003-04-24 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients |
WO1998001117A1 (en) * | 1996-07-08 | 1998-01-15 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
US5709878A (en) * | 1996-08-02 | 1998-01-20 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
US5952226A (en) * | 1996-11-05 | 1999-09-14 | Modex Therapeutiques | Hypoxia responsive EPO producing cells |
US6471992B1 (en) | 1997-02-20 | 2002-10-29 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
US5807594A (en) * | 1997-02-26 | 1998-09-15 | Ducoa, L.P. | Method for enhancing feed efficiency in ruminants with an encapsulating choline composition |
US5919499A (en) * | 1997-03-03 | 1999-07-06 | Lawley, Inc. | Aiding fermentation digestion and metabolism in mammals |
US5961997A (en) * | 1997-03-25 | 1999-10-05 | Swinehart; James M. | Antipruritic composition |
US6240616B1 (en) | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
US10028851B2 (en) * | 1997-04-15 | 2018-07-24 | Advanced Cardiovascular Systems, Inc. | Coatings for controlling erosion of a substrate of an implantable medical device |
US8172897B2 (en) | 1997-04-15 | 2012-05-08 | Advanced Cardiovascular Systems, Inc. | Polymer and metal composite implantable medical devices |
US5910319A (en) * | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
WO1998058549A1 (en) * | 1997-06-24 | 1998-12-30 | Fuisz Technologies Ltd. | Positive hydration method of preparing confectionery and product therefrom |
US6329429B1 (en) * | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
CN1256085C (en) | 1997-07-01 | 2006-05-17 | 美国辉瑞有限公司 | Sertraline salts and substained-release dosage forms of sertraline |
US5874110A (en) * | 1997-07-22 | 1999-02-23 | Fuisz Technologies Ltd. | Entrapping additives in carbohydrate bodies |
US7122615B1 (en) * | 1998-09-10 | 2006-10-17 | Rutgers, The State University Of New Jersey | Polyanhydrides with therapeutically useful degradation products |
US6486214B1 (en) * | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
IN186245B (en) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US6270464B1 (en) | 1998-06-22 | 2001-08-07 | Artemis Medical, Inc. | Biopsy localization method and device |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
NZ330596A (en) | 1998-06-05 | 2001-02-23 | Dec Res | Intravaginal devices allowing for increased uptake of active ingredients |
CA2311311C (en) * | 1997-11-21 | 2008-05-06 | Interag | Biodegradable intra vaginal devices |
US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
US8679534B2 (en) * | 1997-12-12 | 2014-03-25 | Andrx Labs, Llc | HMG-CoA reductase inhibitor extended release formulation |
US20040029962A1 (en) * | 1997-12-12 | 2004-02-12 | Chih-Ming Chen | HMG-COA reductase inhibitor extended release formulation |
US6159968A (en) * | 1998-01-15 | 2000-12-12 | University Of Cincinnati | Activation of chloride channels for correction of defective chloride transport |
US5869090A (en) * | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
US5908838A (en) * | 1998-02-19 | 1999-06-01 | Medics Pharmaceutical Corporation | Method for the treatment of acne |
US6475528B1 (en) | 1998-04-16 | 2002-11-05 | Georg Dietz | Preparation for regenerating collagen |
CA2320135A1 (en) * | 1998-04-16 | 1999-10-28 | Georg Dietz | Preparation for regenerating collagen |
US5939453A (en) * | 1998-06-04 | 1999-08-17 | Advanced Polymer Systems, Inc. | PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers |
DE19825499C2 (en) * | 1998-06-08 | 2003-07-17 | Beiersdorf Ag | Patches containing active ingredients |
US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
US6200590B1 (en) | 1998-08-10 | 2001-03-13 | Naphcare, Inc. | Controlled, phased-release suppository and its method of production |
US5976603A (en) * | 1998-08-26 | 1999-11-02 | Fuisz Technologies Ltd. | Fiber and vitamin-fortified drink composition and beverage and method of making |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6607749B1 (en) * | 1998-09-08 | 2003-08-19 | Smithkline Beecham Corporation | Lipstatin derivative-soluble fiber tablets |
GT199900148A (en) * | 1998-09-10 | 2001-02-28 | Denaturing for the sympathomimetic amine salts. | |
US6171607B1 (en) * | 1998-09-28 | 2001-01-09 | Fuisz Technologies Ltd. | Process and apparatus for producing shearform matrix material |
US6174873B1 (en) | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
US6596401B1 (en) | 1998-11-10 | 2003-07-22 | C. R. Bard Inc. | Silane copolymer compositions containing active agents |
US9669113B1 (en) | 1998-12-24 | 2017-06-06 | Devicor Medical Products, Inc. | Device and method for safe location and marking of a biopsy cavity |
US6356782B1 (en) | 1998-12-24 | 2002-03-12 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US6371904B1 (en) | 1998-12-24 | 2002-04-16 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US6498153B1 (en) | 1998-12-31 | 2002-12-24 | Akzo Nobel N.V. | Extended release growth promoting two component composition |
EP1144384B1 (en) | 1999-01-22 | 2007-10-31 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6866861B1 (en) | 1999-01-29 | 2005-03-15 | Land O'lakes, Inc. | Method and composition for enhancing milk component concentrations |
JP4548623B2 (en) * | 1999-02-24 | 2010-09-22 | 多木化学株式会社 | Biomaterial |
US6676951B1 (en) * | 1999-05-11 | 2004-01-13 | Charles Walton Champ | Host-guest processes and formulations for delivering bio-affecting compounds |
CA2373630A1 (en) * | 1999-05-11 | 2000-11-16 | Charles Walton Champ | Host-guest processes and formulations for delivering bio-affecting compounds |
US20040228887A1 (en) * | 1999-05-11 | 2004-11-18 | Champ Charles W. | Host-guest processes and formulations for delivering bio-affecting compounds |
US6187822B1 (en) * | 1999-06-11 | 2001-02-13 | University Of Medicine & Dentistry Of Nj | Wound treatment through inhibition of adenosine diphosphate ribosyl transferase |
US6440447B1 (en) | 1999-06-22 | 2002-08-27 | Land O'lakes, Inc. | Method and composition for enhancing milk production |
US6726922B1 (en) | 1999-06-28 | 2004-04-27 | Minu, L.L.C. | Process and composition for temporarily suppressing pain |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
AU762291B2 (en) * | 1999-09-30 | 2003-06-19 | Penwest Pharmaceutical Co. | Sustained release matrix systems for highly soluble drugs |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
EP2295043A1 (en) | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
WO2001034123A1 (en) * | 1999-11-08 | 2001-05-17 | Andrx Corporation | Hmg-coa reductase inhibitor extended release formulation |
US20040038948A1 (en) | 1999-12-07 | 2004-02-26 | Uhrich Kathryn E. | Therapeutic compositions and methods |
US6685928B2 (en) * | 1999-12-07 | 2004-02-03 | Rutgers, The State University Of New Jersey | Therapeutic compositions and methods |
ES2169980B1 (en) | 1999-12-17 | 2003-11-01 | Lipotec Sa | MICROCAPSULES FOR THE PROLONGED RELEASE OF PHARMACOS. |
US6579539B2 (en) | 1999-12-22 | 2003-06-17 | C. R. Bard, Inc. | Dual mode antimicrobial compositions |
BR0007360A (en) * | 1999-12-23 | 2001-08-14 | Johnson & Johnson | Controlled release composition |
US6207193B1 (en) * | 1999-12-27 | 2001-03-27 | Stephen E. Feldman | Transdermal drug delivery system |
US6544553B1 (en) * | 1999-12-28 | 2003-04-08 | Watson Pharmaceuticals, Inc. | Dosage forms and methods for oral delivery of progesterone |
JP2003530156A (en) | 2000-04-06 | 2003-10-14 | ユニバーシティ ライセンス ホールディングス インコーポレイテッド | Compositions and methods for promoting wound healing |
JP2002113088A (en) * | 2000-05-25 | 2002-04-16 | Ethicon Inc | Surgical device with antimicrobial action |
EP1301177A2 (en) * | 2000-07-10 | 2003-04-16 | Therics, Inc. | Method and materials for controlling migration of binder liquid in a powder |
AU2001279064A1 (en) * | 2000-07-27 | 2002-02-13 | Rutgers, The State University | Therapeutic azo-compounds for drug delivery |
JP5244279B2 (en) * | 2000-07-27 | 2013-07-24 | ラトガーズ,ザ ステイト ユニバーシティ | Therapeutic polyesters and polyamides |
WO2002031037A1 (en) * | 2000-10-11 | 2002-04-18 | Union Carbide Chemicals & Plastics Technology Corporation | Compositions comprising crystalline condensation polymers and nucleating agents |
US6620829B2 (en) | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
CN101317825A (en) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | Controlled release hydrocodone formulations |
AU2002220248A1 (en) * | 2000-11-06 | 2002-05-15 | Andrx Pharmaceuticals, Inc. | Once a day antihistamine and decongestant formulation |
NZ527113A (en) * | 2001-02-08 | 2005-04-29 | Pharmacia Corp | Rapid-onset medicament for the treatment of sexual dysfunction |
US6590059B2 (en) * | 2001-05-11 | 2003-07-08 | Ap Pharma, Inc. | Bioerodible polyorthoesters from dioxolane-based diketene acetals |
EP1408876A4 (en) | 2001-06-22 | 2004-09-22 | Durect Corp | Zero-order prolonged release coaxial implants |
US7968119B2 (en) * | 2001-06-26 | 2011-06-28 | Farrell John J | Tamper-proof narcotic delivery system |
KR100840219B1 (en) * | 2001-08-03 | 2008-06-23 | 도레이 가부시끼가이샤 | Resin composition and molded article, film, and fiber each comprising the same |
WO2003013609A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
CN100489280C (en) * | 2001-08-06 | 2009-05-20 | 西南研究会 | Method and apparatus for testing catalytic converter durability |
US6881482B2 (en) | 2001-08-16 | 2005-04-19 | Southwest Research Institute | Microencapsulation using electromagnetic energy and core and shell materials with different dielectric constants and dissipation factors |
BR0212259A (en) * | 2001-08-29 | 2004-10-19 | Ranbaxy Lab Ltd | Controlled release formulation of clarithromycin or tinidazole |
US20030124174A1 (en) * | 2001-10-25 | 2003-07-03 | Endo Pharmaceuticals, Inc | Method for treating non-neuropathic pain |
US6524606B1 (en) | 2001-11-16 | 2003-02-25 | Ap Pharma, Inc. | Bioerodible polyorthoesters containing amine groups |
AU2002362069A1 (en) * | 2001-12-14 | 2003-06-30 | Syed Rizvi | Feminine wipe for symptomatic treatment of vaginitis |
US7255874B1 (en) | 2001-12-21 | 2007-08-14 | Closure Medical Corporation | Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto |
WO2004000301A1 (en) * | 2002-06-19 | 2003-12-31 | Maruha Corporation | Oral preventive/therapeutic agent for skin damage containing diacylglyceryl ether |
US20040005359A1 (en) * | 2002-06-27 | 2004-01-08 | Cheng Xiu Xiu | Controlled release oral dosage form |
AU2003251992A1 (en) * | 2002-07-17 | 2004-02-02 | Rutgers, The State University | Therapeutic devices for patterned cell growth |
US20030017208A1 (en) * | 2002-07-19 | 2003-01-23 | Francis Ignatious | Electrospun pharmaceutical compositions |
US20040120991A1 (en) * | 2002-09-07 | 2004-06-24 | Mars Incorporated | Edible films having distinct regions |
US20050020613A1 (en) * | 2002-09-20 | 2005-01-27 | Alpharma, Inc. | Sustained release opioid formulations and method of use |
BR0314525A (en) * | 2002-10-04 | 2005-07-26 | Pharmacia Corp | Compositions and methods for treating sexual dysfunction |
US9474524B2 (en) | 2002-10-04 | 2016-10-25 | Ethicon, Inc. | Packaged antimicrobial medical device having improved shelf life and method of preparing same |
US9597067B2 (en) | 2002-10-04 | 2017-03-21 | Ethicon, Inc. | Packaged antimicrobial medical device and method of preparing same |
US8133437B2 (en) * | 2002-10-04 | 2012-03-13 | Ethicon, Inc. | Method of preparing an antimicrobial packaged medical device |
US7513093B2 (en) * | 2002-10-04 | 2009-04-07 | Ethicon, Inc. | Method of preparing a packaged antimicrobial medical device |
US8112973B2 (en) | 2002-10-04 | 2012-02-14 | Ethicon, Inc. | Method of making a packaged antimicrobial suture |
US20040220614A1 (en) * | 2002-10-04 | 2004-11-04 | Howard Scalzo | Packaged antimicrobial medical device and method of preparing same |
US20040068293A1 (en) * | 2002-10-04 | 2004-04-08 | Howard Scalzo | Packaged antimicrobial medical device and method of preparing same |
US20060058206A1 (en) * | 2002-11-02 | 2006-03-16 | Venture Management Alliance | Aqueous activated components conveyed in a non-aqueous carrier system |
US8092831B2 (en) * | 2002-11-08 | 2012-01-10 | Andrx Pharmaceuticals, Llc | Antihistamine and decongestant system |
US7045589B2 (en) * | 2002-11-15 | 2006-05-16 | A.P. Pharma, Inc. | Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them |
US20060127425A1 (en) * | 2002-12-10 | 2006-06-15 | Venture Management Alliance, Llc | Encapsulated material released to generate perceivable sensorial indicia of discrete event occurrence |
US8519008B2 (en) | 2003-01-22 | 2013-08-27 | Purina Animal Nutrition Llc | Method and composition for improving the health of young monogastric mammals |
US20040185250A1 (en) * | 2003-02-07 | 2004-09-23 | John Amy T. | Triclosan containing absorbable sutures with extended antimicrobial properties |
WO2004073033A2 (en) * | 2003-02-11 | 2004-08-26 | Venture Management Alliance, Llc | Material incapsulation system |
US20040185119A1 (en) * | 2003-02-26 | 2004-09-23 | Theuer Richard C. | Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency |
US6932930B2 (en) * | 2003-03-10 | 2005-08-23 | Synecor, Llc | Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same |
US20040219229A1 (en) * | 2003-04-30 | 2004-11-04 | Tim Clarot | Migraine relief composition and methods of using and forming same |
WO2005000985A2 (en) * | 2003-06-03 | 2005-01-06 | Medlogic Global Limited | Antimicrobial phenol containing cyanoacrylate adhesive compositions |
US7314640B2 (en) * | 2003-07-11 | 2008-01-01 | Mongkol Sriwongjanya | Formulation and process for drug loaded cores |
US20050042266A1 (en) * | 2003-08-21 | 2005-02-24 | Closure Medical Corporation | Cyanoacrylate compositions containing anti-microbial agent |
US8469036B2 (en) | 2003-11-07 | 2013-06-25 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
EP1689368B1 (en) * | 2003-12-04 | 2016-09-28 | Bend Research, Inc | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
EP1691786A1 (en) * | 2003-12-04 | 2006-08-23 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
DK1691787T3 (en) * | 2003-12-04 | 2008-09-22 | Pfizer Prod Inc | Method of Forming Small Particles |
KR20080064209A (en) * | 2003-12-04 | 2008-07-08 | 화이자 프로덕츠 인코포레이티드 | Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
CN1889933A (en) * | 2003-12-04 | 2007-01-03 | 辉瑞产品公司 | Azithromycin multiparticulate dosage forms by liquid-based processes |
US20050136112A1 (en) * | 2003-12-19 | 2005-06-23 | Pediamed Pharmaceuticals, Inc. | Oral medicament delivery system |
US8110214B2 (en) * | 2003-12-23 | 2012-02-07 | Land O'lakes Purina Feed Llc | Method and composition for enhancing milk production and milk component concentrations |
US20050163843A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Alprazolam formulations |
US7892218B2 (en) * | 2004-03-03 | 2011-02-22 | Rostam Ltd. | pH reducing formulation |
US20060030538A1 (en) * | 2004-07-21 | 2006-02-09 | Medtronic, Inc. | Methods for reducing or preventing localized fibrosis using SiRNA |
US7767652B2 (en) * | 2004-07-21 | 2010-08-03 | Medtronic, Inc. | Medical devices and methods for reducing localized fibrosis |
WO2006078320A2 (en) | 2004-08-04 | 2006-07-27 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
WO2006026504A2 (en) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Mucoadhesive oral formulations of high permeability, high solubility drugs |
MX2007003032A (en) | 2004-09-21 | 2007-05-21 | Hypnion Inc | Loxapine analogs and methods of use thereof. |
US20060062811A1 (en) * | 2004-09-21 | 2006-03-23 | Szymczak Christopher E | Medicinal cooling emulsions |
US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
US20060083724A1 (en) * | 2004-10-01 | 2006-04-20 | Hilst Todd W | Compositions for the treatment of femal sexual dysfunction |
DE102005004318A1 (en) * | 2005-01-31 | 2006-08-10 | Ethicon Gmbh | Surgical seam system |
WO2006107390A2 (en) | 2005-04-04 | 2006-10-12 | Kronos Advanced Technologies, Inc. | An electrostatic fluid accelerator for and method of controlling a fluid flow |
US20080242642A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US8252776B2 (en) * | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US7541347B2 (en) * | 2007-04-02 | 2009-06-02 | Medicis Pharmaceutical Coropration | Minocycline oral dosage forms for the treatment of acne |
US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
US7544373B2 (en) | 2007-04-02 | 2009-06-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
EP1924298B1 (en) * | 2005-09-15 | 2010-07-14 | Aesculap AG | Biocompatible antimicrobial suture material |
US7727996B2 (en) | 2005-09-29 | 2010-06-01 | Elan Pharmaceuticals, Inc. | Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 |
BRPI0616687A2 (en) | 2005-09-29 | 2011-06-28 | Elan Pharm Inc | pyrimidinyl amide compounds that inhibit vla-4 mediated leukocyte adhesion |
US7942867B2 (en) * | 2005-11-09 | 2011-05-17 | The Invention Science Fund I, Llc | Remotely controlled substance delivery device |
US20070167925A1 (en) * | 2006-01-19 | 2007-07-19 | William Jacqmein | Catheter with releasably coupled distal legs |
JP5135235B2 (en) | 2006-02-27 | 2013-02-06 | エラン ファーマシューティカルズ,インコーポレイテッド | Pyrimidinylsulfonamide compounds that inhibit leukocyte adhesion mediated by VAL-4 |
WO2007100881A2 (en) * | 2006-02-28 | 2007-09-07 | Tyco Healthcare Group Lp | Antimicrobial medical devices |
US7901705B2 (en) * | 2006-02-28 | 2011-03-08 | Tyco Healthcare Group Lp | Antimicrobial releasing polymers |
BRPI0708842A2 (en) * | 2006-03-28 | 2011-06-14 | Gelesis Inc | use of polymeric materials with other substances to increase performance |
SG172664A1 (en) * | 2006-06-01 | 2011-07-28 | Schering Plough Healthcare | Phenylephrine pharmaceutical formulations and compositions for colonic absorption |
CN101472561A (en) * | 2006-06-01 | 2009-07-01 | 先灵公司 | Phenylphrine pulsed release formulations and pharmaceutical compositions |
AU2007266574A1 (en) * | 2006-06-01 | 2007-12-06 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
NZ573174A (en) * | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
AU2007254826B2 (en) * | 2006-06-01 | 2013-10-24 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions for sustained release of phenyephrine |
DK2041071T3 (en) | 2006-06-29 | 2014-09-01 | Kinex Pharmaceuticals Llc | BIARLYL COMPOSITIONS AND PROCEDURES FOR MODULATING A CHINA CASE |
US20080014252A1 (en) * | 2006-07-14 | 2008-01-17 | Delprete Keith | Topical compositions with long lasting effect |
US9265866B2 (en) * | 2006-08-01 | 2016-02-23 | Abbott Cardiovascular Systems Inc. | Composite polymeric and metallic stent with radiopacity |
EP2102144A4 (en) | 2006-09-13 | 2011-03-23 | Univ Rutgers | Active agents and their oligomers and polymers |
US8513329B2 (en) | 2006-10-31 | 2013-08-20 | Bio-Tec Environmental, Llc | Chemical additives to make polymeric materials biodegradable |
PL2087033T3 (en) * | 2006-10-31 | 2020-06-01 | Bio-Tec Environmental, Llc | Chemical additives to make polymeric materials biodegradable |
CN101848706A (en) * | 2007-06-01 | 2010-09-29 | 先灵-普劳健康护理产品公司 | Pharmaceutical composition comprising a substrate and a coating containing an active ingredient and polyvinylalcohol |
WO2009051848A1 (en) | 2007-10-20 | 2009-04-23 | Kinex Pharmaceuticals, Llc | Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof |
PE20091084A1 (en) * | 2007-12-07 | 2009-07-23 | Schering Plough Healthcare | PHARMACEUTICAL FORMULATIONS OF PHENYLPHRINE AND COMPOSITIONS FOR TRANSMUCOSAL ABSORPTION |
ES2718612T3 (en) | 2007-12-20 | 2019-07-03 | Evonik Corp | Procedure for preparing microparticles that have a low volume of residual solvent |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
WO2009140246A2 (en) | 2008-05-12 | 2009-11-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
WO2010017310A1 (en) | 2008-08-06 | 2010-02-11 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | Solute concentration measurement device and related methods |
CN102459179A (en) | 2009-04-27 | 2012-05-16 | 艾伦药物公司 | Pyridinone antagonists of alpha-4 integrins |
US9848634B2 (en) * | 2009-06-30 | 2017-12-26 | Philip Morris Products S.A. | Smokeless tobacco product |
WO2011014704A2 (en) | 2009-07-30 | 2011-02-03 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CA2803636C (en) | 2010-07-02 | 2017-05-16 | The Procter & Gamble Company | Detergent product and method for making same |
CA2803371C (en) | 2010-07-02 | 2016-04-19 | The Procter & Gamble Company | Process for making films from nonwoven webs |
WO2012003365A1 (en) | 2010-07-02 | 2012-01-05 | The Procter & Gamble Company | Filaments comprising an ingestible active agent nonwoven webs and methods for making same |
MX2012015187A (en) | 2010-07-02 | 2013-05-09 | Procter & Gamble | Method for delivering an active agent. |
MX2012015174A (en) | 2010-07-02 | 2013-05-09 | Procter & Gamble | Filaments comprising an active agent nonwoven webs and methods for making same. |
MX2013000201A (en) | 2010-07-02 | 2013-08-21 | Procter & Gamble | Methods of delivering a health care active by administering personal health care articles comprising a filament. |
US8741317B2 (en) | 2010-08-19 | 2014-06-03 | Rutgers, The State University Of New Jersey | Slow-degrading polymers comprising salicylic acid for undelayed and sustained drug delivery |
US8692001B2 (en) | 2010-10-27 | 2014-04-08 | Dynamix Pharmaceuticals Ltd. | Sulfonamides for the modulation of PKM2 |
WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
WO2012122370A2 (en) | 2011-03-08 | 2012-09-13 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
WO2012160447A1 (en) | 2011-05-25 | 2012-11-29 | Dynamix Pharmaceuticals Ltd. | 3, 5 -diphenyl- substituted pyrazolines for the treatment of cancer, proliferative, inflammatory or autoimmune diseases |
DK2718290T3 (en) | 2011-06-07 | 2016-08-15 | Clevexel Pharma | Compositions and Methods for Modulating a Kinase |
CN103889434B (en) * | 2011-06-21 | 2017-02-15 | Bvw控股公司 | Medical device comprising boswellic acid |
US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
US8658199B2 (en) | 2012-02-01 | 2014-02-25 | Purina Animal Nutrition Llc | Systems and methods for feeding sugar alcohol to ruminants during periods of heat stress |
US10245025B2 (en) | 2012-04-06 | 2019-04-02 | Ethicon, Inc. | Packaged antimicrobial medical device having improved shelf life and method of preparing same |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
IN2014DN11205A (en) | 2012-06-20 | 2015-10-02 | Eutropics Pharmaceuticals Inc | |
ES2938586T3 (en) * | 2012-06-27 | 2023-04-12 | Medincell S A | Biodegradable drug release for hydrophobic compositions |
US9144579B2 (en) | 2012-08-17 | 2015-09-29 | Rutgers, The State University Of New Jersey | Polyesters and methods of use thereof |
CN109999040A (en) | 2012-08-30 | 2019-07-12 | 阿西纳斯公司 | Protein tyrosine kinase regulator |
US20140120057A1 (en) | 2012-10-25 | 2014-05-01 | Rutgers, The State University Of New Jersey | Polymers and methods thereof for wound healing |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9387250B2 (en) | 2013-03-15 | 2016-07-12 | Rutgers, The State University Of New Jersey | Therapeutic compositions for bone repair |
WO2014144661A1 (en) | 2013-03-15 | 2014-09-18 | Aprecia Pharmaceuticals Compny | Rapidly dispersible dosage form of topiramate |
EP2968354B1 (en) | 2013-03-15 | 2019-11-13 | Aprecia Pharmaceuticals LLC | Rapidly dispersible dosage form of oxcarbazepine |
ES2688880T3 (en) | 2013-03-15 | 2018-11-07 | Aprecia Pharmaceuticals LLC | Rapid dispersion dosage form containing levetiracetam |
US9339489B2 (en) | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
WO2014197137A1 (en) * | 2013-04-29 | 2014-12-11 | Howard Brooks-Korn | Diversion-resistant formulation |
US9862672B2 (en) | 2013-05-29 | 2018-01-09 | Rutgers, The State University Of New Jersey | Antioxidant-based poly(anhydride-esters) |
CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9579257B2 (en) | 2013-08-20 | 2017-02-28 | Anutra Medical, Inc. | Haptic feedback and audible output syringe |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9970303B2 (en) | 2014-05-13 | 2018-05-15 | Entrotech, Inc. | Erosion protection sleeve |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
WO2015191742A1 (en) | 2014-06-13 | 2015-12-17 | Rutgers, The State University Of New Jersey | Process and intermediates for preparing poly(anhydride-esters) |
CA2897038C (en) | 2014-07-14 | 2016-10-04 | Novicol International Holding Inc. | Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
CA3074394C (en) * | 2015-03-04 | 2023-01-31 | The Procter & Gamble Company | Fibrous elements, fibrous structures, and products comprising a deterrent agent and methods for making same |
WO2016164898A1 (en) | 2015-04-10 | 2016-10-13 | Rutgers, The State University Of New Jersey | Kojic acid polymers |
US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
JP2018519294A (en) * | 2015-06-22 | 2018-07-19 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドJohnson & Johnson Consumer Inc. | Multi-layer topical article for providing beneficial effects on skin |
HRP20231453T1 (en) | 2015-11-16 | 2024-03-01 | Medincell S.A. | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
EP3497099B1 (en) | 2016-08-12 | 2022-03-02 | Athenex, Inc. | Biaryl compositions and methods for modulating a kinase cascade |
US11053466B2 (en) | 2018-01-26 | 2021-07-06 | The Procter & Gamble Company | Water-soluble unit dose articles comprising perfume |
KR102433420B1 (en) | 2018-01-26 | 2022-08-18 | 더 프록터 앤드 갬블 캄파니 | Water-Soluble Articles and Related Methods |
JP7110356B2 (en) | 2018-01-26 | 2022-08-01 | ザ プロクター アンド ギャンブル カンパニー | Water soluble unit dose article containing perfume |
KR20200086739A (en) | 2018-01-26 | 2020-07-17 | 더 프록터 앤드 갬블 캄파니 | Water soluble unit dose article containing enzyme |
WO2019168829A1 (en) | 2018-02-27 | 2019-09-06 | The Procter & Gamble Company | A consumer product comprising a flat package containing unit dose articles |
US11504268B2 (en) * | 2018-06-27 | 2022-11-22 | Ethicon, Inc. | Wound treatment system |
US10982176B2 (en) | 2018-07-27 | 2021-04-20 | The Procter & Gamble Company | Process of laundering fabrics using a water-soluble unit dose article |
EP3883546A1 (en) | 2018-11-21 | 2021-09-29 | Rosemont Pharmaceuticals Ltd | Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability |
WO2020159860A1 (en) | 2019-01-28 | 2020-08-06 | The Procter & Gamble Company | Recycleable, renewable, or biodegradable package |
EP3712237A1 (en) | 2019-03-19 | 2020-09-23 | The Procter & Gamble Company | Fibrous water-soluble unit dose articles comprising water-soluble fibrous structures |
JP7381613B2 (en) | 2019-06-28 | 2023-11-15 | ザ プロクター アンド ギャンブル カンパニー | Dissolvable solid fibrous article containing anionic surfactant |
JP2023533478A (en) | 2020-06-26 | 2023-08-03 | アプレシア・ファーマスーティカルズ・エルエルシー | Rapidly dispersible tablet with internal cavity |
WO2022027067A1 (en) | 2020-07-31 | 2022-02-03 | The Procter & Gamble Company | Water-soluble fibrous pouch containing prills for hair care |
WO2022124914A1 (en) | 2020-12-08 | 2022-06-16 | Ruminant Biotech Corp Limited | Improvements to devices and methods for delivery of substances to animals |
CN113304307B (en) * | 2021-05-21 | 2022-03-25 | 浙江大学 | Polyphosphazene-based hydrogel wound dressing with antibacterial and wet surface adhesion properties and preparation method thereof |
Family Cites Families (227)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2918404A (en) * | 1956-07-30 | 1959-12-22 | Ortho Pharma Corp | Solid compressed amino acid spermicidal vehicle |
US3131428A (en) * | 1958-12-19 | 1964-05-05 | Celanese Corp | Spinneret and spinning method |
NL136087C (en) * | 1962-01-15 | |||
GB1043406A (en) * | 1962-05-23 | 1966-09-21 | Nippon Oil Co Ltd | The preparation of petroleum resins |
US3308221A (en) * | 1963-05-14 | 1967-03-07 | Allied Chem | Melt spinning of modified cross section yarn |
US3345352A (en) * | 1964-02-21 | 1967-10-03 | Allied Chem | Catalytic process for the thermal degradation of polyolefins |
DE1486334A1 (en) * | 1964-11-16 | 1969-04-17 | Eastman Kodak Co | Use of synthetic polymers for the production of packaging and packaging materials, especially for food |
US3740391A (en) * | 1965-07-12 | 1973-06-19 | American Cyanamid Co | Thermosetting glyoxalated ionic glucopyranosyl polymer and wet strength paper having a content thereof |
US3299568A (en) * | 1966-03-01 | 1967-01-24 | Research Corp | Compositions plasticized with sulphur |
US3454510A (en) * | 1966-03-03 | 1969-07-08 | Eastman Kodak Co | Polyolefin compositions and degradable films made therefrom |
DE1811024A1 (en) * | 1967-12-06 | 1969-10-16 | Chisso Corp | Degradable polyolefin blends |
US3592792A (en) * | 1968-07-24 | 1971-07-13 | Eastman Kodak Co | Agricultural plastic film |
US3887699A (en) * | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
GB1311855A (en) * | 1969-07-23 | 1973-03-28 | Dow Corning Ltd | Polypropylene |
GB1282512A (en) * | 1969-09-05 | 1972-07-19 | Ethylene Plastique Sa | Polyolefin compositions |
US3590528A (en) * | 1969-09-25 | 1971-07-06 | Princeton Chemical Res Inc | Decomposable polybutene-1 agricultural mulch film |
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
GB1362363A (en) * | 1970-04-27 | 1974-08-07 | Univ Toronto | Photodegradable polymers |
US3853814A (en) * | 1970-04-27 | 1974-12-10 | J Guillet | Photodegradable polymers of methyl methacrylate and unsaturated ketones |
US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US3647111A (en) * | 1970-06-01 | 1972-03-07 | Biocor Corp | Biodegradable container |
GB1356107A (en) | 1970-07-22 | 1974-06-12 | Scott G | Polymer compositions |
US3673134A (en) * | 1970-08-03 | 1972-06-27 | Du Pont | Agricultural mulch |
US3864293A (en) * | 1970-08-25 | 1975-02-04 | Seikisui Chemical Co Ltd | Photo-Degradable Styrene Resin Composition |
GB1346650A (en) | 1970-09-18 | 1974-02-13 | Sekisui Chemical Co Ltd | Photo-degradable resin compositions |
AU3476771A (en) * | 1970-11-02 | 1973-05-03 | Imperial Chemical Industries Limited | Plastics composition |
US3886683A (en) * | 1970-11-27 | 1975-06-03 | Princeton Chemical Res Inc | Degradable plastic |
US3686000A (en) * | 1971-01-11 | 1972-08-22 | Gen Foods Corp | Moisture resistant sugar filaments |
US3707056A (en) * | 1971-05-10 | 1972-12-26 | Texaco Inc | Decomposable polyolefin agricultural mulch |
GB1382062A (en) * | 1971-06-10 | 1975-01-29 | Ici Ltd | Plastics composition |
BE785814A (en) * | 1971-07-06 | 1973-01-04 | Dow Chemical Co | PHOTO-DEGRADABLE ETHYLENE POLYMER COMPOSITIONS |
US3960150A (en) * | 1971-09-09 | 1976-06-01 | Alza Corporation | Bioerodible ocular device |
US3981303A (en) * | 1971-09-09 | 1976-09-21 | Alza Corporation | Bioerodible ocular device |
US3986510A (en) * | 1971-09-09 | 1976-10-19 | Alza Corporation | Bioerodible ocular device |
SE372024B (en) * | 1971-09-14 | 1974-12-09 | Akerlund & Rausing Ab | |
DE2160223A1 (en) * | 1971-12-04 | 1973-06-07 | Hoechst Ag | LIGHT-DEGRADABLE THERMOPLASTIC MOLDING COMPOUNDS ON A POLYACETAL BASE |
US4476255A (en) | 1971-11-01 | 1984-10-09 | Owens-Illinois, Inc. | Photoreactive plastic composition and articles degradable by ultraviolet radiation and a process for their manufacture |
US3888804A (en) * | 1971-11-02 | 1975-06-10 | Bio Degradable Plastics | Photodegradable hydrocarbon polymers |
GB1370286A (en) * | 1971-11-08 | 1974-10-16 | Ici Ltd | Wrapping material string and containers made form polyolefine compositions |
US4038228A (en) | 1971-11-19 | 1977-07-26 | Owens-Illinois, Inc. | Degradable plastic composition containing a transition metal salt of a highly unsaturated organic acid |
US3839297A (en) * | 1971-11-22 | 1974-10-01 | Ethicon Inc | Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures |
US4056499A (en) | 1971-12-08 | 1977-11-01 | Owens-Illinois, Inc. | Degradable polymeric composition |
US3797690A (en) * | 1971-12-08 | 1974-03-19 | Owens Illinois Inc | Preparation of degradable polymeric material |
BE793006A (en) * | 1971-12-20 | 1973-06-19 | Union Carbide Corp | DEGRADABLE POLYOLEFIN FILM |
JPS518411B2 (en) * | 1971-12-28 | 1976-03-16 | ||
US3835108A (en) * | 1972-02-15 | 1974-09-10 | American Home Prod | Process for preparing the releasing hormone of luteinizing hormone(lh)and of follicle stimulating hormone(fsh),salts and compositions thereof,and intermediates therefor |
US4101720A (en) | 1972-03-01 | 1978-07-18 | Owens-Illinois, Inc. | Degradable plastic |
US3941759A (en) * | 1972-03-01 | 1976-03-02 | Owens-Illinois, Inc. | Degradable plastics containing dual-function additive system |
JPS5118265B2 (en) * | 1972-03-14 | 1976-06-08 | ||
JPS527014B2 (en) * | 1972-03-24 | 1977-02-26 | ||
US3994855A (en) * | 1972-04-18 | 1976-11-30 | Ab Akerlund & Rausing | Degradable polymer composition and process for preparing the same |
NO139560C (en) * | 1972-04-29 | 1979-04-04 | Takeda Chemical Industries Ltd | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY EFFECTIVE NONAPEPTIDAMIDE DERIVATIVES |
US4021388A (en) | 1972-05-18 | 1977-05-03 | Coloroll Limited | Synthetic resin sheet material |
US4016117A (en) | 1972-05-18 | 1977-04-05 | Coloroll Limited | Biodegradable synthetic resin sheet material containing starch and a fatty material |
US4067836A (en) | 1972-06-28 | 1978-01-10 | Union Carbide Corporation | Environmentally degradable compositions exposed to actinic or ionizing radiation and process |
US4495311A (en) | 1972-07-06 | 1985-01-22 | Princeton Polymer Laboratories, Inc. | Degradable hydrocarbon polymers |
US3830764A (en) * | 1972-07-06 | 1974-08-20 | Princeton Polymer Lab | Degradable hydrocarbon polymers |
US3951821A (en) * | 1972-07-14 | 1976-04-20 | The Dow Chemical Company | Disintegrating agent for tablets |
US3932319A (en) * | 1972-07-28 | 1976-01-13 | Union Carbide Corporation | Blends of biodegradable thermoplastic dialkanoyl polymer, a naturally occurring biodegradable product, a plastic additive and a filler |
US3921333A (en) * | 1972-07-28 | 1975-11-25 | Union Carbide Corp | Transplanter containers made from biodegradable-environmentally degradable blends |
US3844987A (en) * | 1972-07-28 | 1974-10-29 | Union Carbide Corp | Contour adapted passenger loading ramp biodegradable transplanter containers |
US3867324A (en) * | 1972-07-28 | 1975-02-18 | Union Carbide Corp | Environmentally degradable-biodegradable blend of an oxyalkanoyl polymer and an environmentally degradable ethylene polymer |
US3923729A (en) * | 1972-07-28 | 1975-12-02 | Union Carbide Corp | Biodegradable transplanter containers |
US3850862A (en) * | 1972-07-28 | 1974-11-26 | Union Carbide Corp | Blends of a biodegradable thermoplastic dialkanoyl polymer and a naturally occurring biodegradable product |
US3931068A (en) * | 1972-07-28 | 1976-01-06 | Union Carbide Corporation | Blends of biodegradable thermoplastic oxyalkanoyl polymer, a naturally occurring biodegradable product, filler and plastic additive |
US3901838A (en) * | 1972-07-28 | 1975-08-26 | Union Carbide Corp | Environmentally degradable biodegradable blends of a dialkanoyl polymer and an environmentally degradable ethylene polymer |
US3847852A (en) * | 1972-08-23 | 1974-11-12 | Bell & Richardson Inc De | Outdoor degradable hydrocarbon plastic |
US3839311A (en) * | 1972-09-06 | 1974-10-01 | Phillips Petroleum Co | Polymer pro-oxidant comprising hydroxy-substituted 2,4-pentadienophenones |
US4207221A (en) | 1972-09-13 | 1980-06-10 | Owens-Illinois, Inc. | Degradable plastic composition containing unsaturated wax |
FR2199757A5 (en) * | 1972-09-20 | 1974-04-12 | Ethylene Plastique Sa | |
US4056665A (en) | 1972-10-26 | 1977-11-01 | Owens-Illinois, Inc. | Composition and process |
US4360606A (en) | 1972-10-26 | 1982-11-23 | Owens-Illinois, Inc. | Photo-degradable polymer compositions |
US3840512A (en) * | 1972-11-09 | 1974-10-08 | Ici Ltd | Degradable plastics composition |
US3875300A (en) * | 1972-12-18 | 1975-04-01 | Ortho Pharma Corp | Composition for sustained release of a medicament and method of using same |
US3826796A (en) * | 1972-12-20 | 1974-07-30 | American Home Prod | P-glu-his-leu-arg-pro-gly-nh2 and intermediates |
US3989611A (en) * | 1973-01-08 | 1976-11-02 | The Firestone Tire & Rubber Company | Radiation treatment of polymers containing isobutylene |
US4100334A (en) | 1973-01-15 | 1978-07-11 | Snam Progetti S.P.A. | Process for rendering polymers degradable and polymers obtained thereby |
US3832312A (en) * | 1973-03-12 | 1974-08-27 | Arco Polymers Inc | Process for making foamed styrene polymers photodegradable |
JPS49119972A (en) * | 1973-03-19 | 1974-11-15 | ||
US3903029A (en) * | 1973-03-20 | 1975-09-02 | Hall Howard E C | Biodegradable alpha polyolefin compositions containing a mixture of para-alkanolamino phenols |
US3917545A (en) * | 1973-04-05 | 1975-11-04 | Arco Polymers Inc | Photodegradable styrene polymer foams containing a hydrocarbon photosensitizer |
US3824227A (en) * | 1973-04-11 | 1974-07-16 | American Home Prod | Decapeptide (d-phe)2 analog of luteinizing hormones releasing factor and intermediates thereof |
US3991766A (en) * | 1973-05-31 | 1976-11-16 | American Cyanamid Company | Controlled release of medicaments using polymers from glycolic acid |
GB1458817A (en) | 1973-07-09 | 1976-12-15 | Charbonnages Ste Chimique | Photodegradable olefin polymer compositions |
US3850363A (en) * | 1973-07-16 | 1974-11-26 | L Jacobs | Carton |
FR2238700B1 (en) | 1973-07-24 | 1977-10-14 | Takeda Chemical Industries Ltd | |
US3925525A (en) * | 1973-08-10 | 1975-12-09 | Celanese Corp | Spinning method |
GB1424747A (en) * | 1973-08-28 | 1976-02-11 | Ucb Sa | Method and apparatus for the continuous dehydration of maleic acid |
CS180644B2 (en) * | 1973-09-29 | 1978-01-31 | Takeda Chemical Industries Ltd | Process for preparing nonapeptides |
JPS5726506B2 (en) * | 1974-03-08 | 1982-06-04 | ||
IT998906B (en) * | 1973-10-24 | 1976-02-20 | Snam Progetti | PROCEDURE FOR BENDING DEGRADABLE POLYMERS |
IT998905B (en) * | 1973-10-24 | 1976-02-20 | Snam Progetti | PROCEDURE TO MAKE DEGRADABLE POLYMERS AND DEGRADABLE POLYMERS SO OBTAINED |
NL157021B (en) * | 1973-11-15 | 1978-06-15 | Degussa | PROCESS FOR PREPARING POLYCARBOXYLATES WITH IMPROVED BIODEGRADABILITY. |
US4003846A (en) * | 1973-11-16 | 1977-01-18 | Ciba-Geigy Corporation | Process for the encapsulating of substances immiscible with water |
AU7496074A (en) * | 1973-11-21 | 1976-05-06 | Snam Progetti | Transforming hydrocarbon polymers into photodegradable |
US3892723A (en) * | 1974-02-04 | 1975-07-01 | American Home Prod | P-Glu-Trp-Ser-Tyr-D-Pgl-Leu-Arg-Pro-Gly-NH{HD 2 {B and intermediates |
NL174734C (en) * | 1974-02-18 | 1984-08-01 | Tno | METHOD FOR PREPARING PLASTIC MATERIALS DEGRADABLE UNDER THE INFLUENCE OF WATER, AND ARTICLES PRODUCED FROM PLASTIC MATERIALS OBTAINED USING THE METHOD |
US3981856A (en) * | 1974-03-07 | 1976-09-21 | Princeton Polymer Laboratories, Incorporated | Degradable hydrocarbon polymers containing a metal compound and a benzotriazole |
US3968095A (en) * | 1974-03-22 | 1976-07-06 | The United States Of America As Represented By The Secretary Of Agriculture | Photodegradable plastics containing an N-halo amide |
JPS5214170B2 (en) * | 1974-03-30 | 1977-04-20 | ||
US3896105A (en) * | 1974-04-01 | 1975-07-22 | American Home Prod | (n-propionyl) -gly-cys-lys-asn-phe-phe-trp-lys-thr-phe-thr-ser-cys-oh and intermediates |
LU69892A1 (en) * | 1974-04-19 | 1976-03-17 | ||
IT1015654B (en) | 1974-07-03 | 1977-05-20 | Montedison Spa | DABLE PHOTODEGRA POLYMER COMPOSITIONS WITH HIGH THERMAL STABILITY |
US4136145A (en) | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
DE2436260B1 (en) | 1974-07-27 | 1975-04-30 | Bayer Ag, 5090 Leverkusen | Degradable plastic composition |
US3932338A (en) * | 1974-08-22 | 1976-01-13 | The United States Of America As Represented By The Secretary Of Agriculture | Photodegradable plastics containing β-halophenyl ketones |
US4011375A (en) * | 1974-11-26 | 1977-03-08 | The United States Of America As Represented By The Secretary Of Agriculture | Photodegradable plastics containing halogenated diphenyl ethanes |
US3968094A (en) * | 1974-11-26 | 1976-07-06 | The United States Of America As Represented By The Secretary Of The Department Of Agriculture | Photodegradable plastics containing haloolefins |
US3954104A (en) * | 1974-11-27 | 1976-05-04 | Personal Products Company | Water-dispersible, biodegradable compositions and containers and the like made therefrom |
US4038227A (en) | 1975-01-03 | 1977-07-26 | Bio-Degradable Plastics, Inc. | Photodegradable polyolefins containing an aromatic ketone, ferric stearate, and a pigment |
US3968096A (en) * | 1975-01-23 | 1976-07-06 | The United States Of America As Represented By The Secretary Of Agriculture | Photodegradable polyolefins containing an halogenated nitrile |
US3929723A (en) * | 1975-01-23 | 1975-12-30 | Us Agriculture | Photodegradable polyolefins containing sulfenyl halides |
US4131648A (en) | 1975-01-28 | 1978-12-26 | Alza Corporation | Structured orthoester and orthocarbonate drug delivery devices |
US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US3991033A (en) * | 1975-01-30 | 1976-11-09 | E. I. Du Pont De Nemours & Company | Photosensitive and degradable polyoxymethylene polymers and their application in imaging |
US3994869A (en) * | 1975-02-18 | 1976-11-30 | Ici United States Inc. | Photodegradable polyolefins containing aryl-substituted 1,3-diones |
US4042765A (en) | 1975-03-27 | 1977-08-16 | Exxon Research And Engineering Co. | Photodegradable plastic compositions containing nitrogen heterocyclic compounds |
US4037034A (en) | 1975-03-27 | 1977-07-19 | Exxon Research And Engineering Company | Photodegradable polyolefin composition containing a dinaphthylphthalate |
FR2307840A1 (en) | 1975-04-17 | 1976-11-12 | Charbonnages Ste Chimique | LIGHT DEGRADABLE POLYMERIC COMPOSITIONS |
US3978033A (en) * | 1975-04-23 | 1976-08-31 | Ici United States Inc. | Difurfurylidene cycloalkanones as photoactive prodegradants for polyolefins |
US4076798A (en) | 1975-05-29 | 1978-02-28 | American Cyanamid Company | High molecular weight polyester resin, the method of making the same and the use thereof as a pharmaceutical composition |
US4017668A (en) | 1975-05-30 | 1977-04-12 | The United States Of America As Represented By The Secretary Of Agriculture | Photodegradable polyolefin composition containing an halogenated isocyanuric acid |
US4012565A (en) | 1975-05-30 | 1977-03-15 | The United States Of America As Represented By The Secretary Of Agriculture | Photodegradable polyolefin composition containing an N-halo hydantoin |
US4017667A (en) | 1975-05-30 | 1977-04-12 | The United States Of America As Represented By The Secretary Of Agriculture | Photodegradable polyolefin composition containing an N-halo benzenesulphonamide |
US4009325A (en) * | 1975-05-30 | 1977-02-22 | The United States Of America As Represented By The Secretary Of Agriculture | Photodegradable polyolefin composition containing an N-halo urethane |
US4010125A (en) * | 1975-06-12 | 1977-03-01 | Schally Andrew Victor | [D-Trp6 ]-LH-RH and intermediates therefor |
US4010196A (en) * | 1975-06-25 | 1977-03-01 | American Home Products Corporation | Linear polyester salts |
US3967623A (en) * | 1975-06-30 | 1976-07-06 | Johnson & Johnson | Disposable absorbent pad |
US3992342A (en) * | 1975-07-10 | 1976-11-16 | Ricoh Co., Ltd. | Non-aqueous dispersion and process of preparing same |
US4066568A (en) | 1975-08-07 | 1978-01-03 | Nippon Pulp Industry Company Limited | Method of producing microcapsules |
US4017666A (en) | 1975-08-08 | 1977-04-12 | The United States Of America As Represented By The Secretary Of Agriculture | Photodegradable polyolefins containing an haloalkyl disulfide |
US4020249A (en) | 1975-08-08 | 1977-04-26 | The United States Of America As Represented By The Secretary Of Agriculture | Photodegradable polyolefins containing haloalkyl- or halobenzene-sulfonyl halides |
US4039731A (en) | 1975-08-08 | 1977-08-02 | The United States Of America As Represented By The Secretary Of Agriculture | Photodegradable polyolefins containing nitrohaloalkanes |
US4156666A (en) | 1975-10-31 | 1979-05-29 | Shiseido Company, Ltd. | Degradable synthetic resin compositions |
US4098728A (en) | 1976-01-02 | 1978-07-04 | Solomon Rosenblatt | Medical surgical sponge and method of making same |
US4072326A (en) | 1976-07-19 | 1978-02-07 | Velo-Bind, Inc. | Wrap-around cover for books |
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US4042763A (en) | 1976-10-08 | 1977-08-16 | Gulf Research & Development Company | Photodegradable resin compositions |
US4218409A (en) | 1977-02-07 | 1980-08-19 | Eastman Kodak Company | Encapsulating method |
US4107071A (en) | 1977-02-16 | 1978-08-15 | Capsulated Systems, Inc. | Method of producing microcapsules and resulting product |
US4147683A (en) | 1977-03-07 | 1979-04-03 | E. I. Du Pont De Nemours And Company | Fluorocarbon polymer-polymeric adjunct coating compositions stabilized against discoloration |
US4108470A (en) | 1977-05-18 | 1978-08-22 | Caterpillar Tractor Co. | Suspension system for tandem axle vehicles |
US4211769A (en) | 1977-08-24 | 1980-07-08 | Takeda Chemical Industries, Ltd. | Preparations for vaginal administration |
US4166800A (en) | 1977-08-25 | 1979-09-04 | Sandoz, Inc. | Processes for preparation of microspheres |
US4177255A (en) | 1977-09-02 | 1979-12-04 | Eastman Kodak Company | Rumen-stable pellets |
US4181708A (en) | 1977-09-02 | 1980-01-01 | Eastman Kodak Company | Rumen-stable pellets |
US4181709A (en) | 1977-09-02 | 1980-01-01 | Eastman Kodak Company | Rumen-stable pellets |
US4196187A (en) | 1977-09-02 | 1980-04-01 | Eastman Kodak Company | Rumen-stable pellets |
US4181710A (en) | 1977-09-02 | 1980-01-01 | Eastman Kodak Company | Rumen-stable pellets |
GB1600496A (en) | 1977-09-16 | 1981-10-14 | Coloroll Ltd | Plasticsbased composition |
IL52974A0 (en) | 1977-09-21 | 1977-11-30 | Plastopil Hazorea | Agricultural process film products for carrying out the process and controllably degradable polymer compositions for making said film products |
US4133784A (en) | 1977-09-28 | 1979-01-09 | The United States Of America As Represented By The Secretary Of Agriculture | Biodegradable film compositions prepared from starch and copolymers of ethylene and acrylic acid |
US4197375A (en) | 1977-12-12 | 1980-04-08 | Chevron Research Company | Photodegradability of plastic polyolefins |
US4256851A (en) | 1977-12-12 | 1981-03-17 | Owens-Illinois, Inc. | Degradable plastic composition containing unsaturated alcohol or ester thereof |
US4212955A (en) | 1978-01-19 | 1980-07-15 | Owens-Illinois, Inc. | Degradable plastic composition containing ortho ester |
US4224416A (en) | 1978-04-10 | 1980-09-23 | Owens-Illinois, Inc. | Degradable plastic composition containing amine |
US4215495A (en) | 1978-09-11 | 1980-08-05 | Wagner Donald G | Road grade attachment |
US4234571A (en) | 1979-06-11 | 1980-11-18 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone |
US4256785A (en) | 1979-07-25 | 1981-03-17 | Eastman Kodak Company | Pellet coating process |
US4291015A (en) | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
US4337181A (en) | 1980-01-17 | 1982-06-29 | The United States Of America As Represented By The Secretary Of Agriculture | Biodegradable starch-based blown films |
US4439199A (en) | 1980-02-19 | 1984-03-27 | Alza Corporation | Method for administering immunopotentiator |
EP0035291B1 (en) | 1980-02-29 | 1983-05-11 | Akzo N.V. | Process for carrying out radical reactions and shaped articles of the reaction product |
US4318905A (en) | 1980-06-23 | 1982-03-09 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues |
US4341767A (en) | 1980-10-06 | 1982-07-27 | Syntex Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4500546A (en) | 1980-10-31 | 1985-02-19 | International Telephone And Telegraph Corporation | Suspensions containing microfibrillated cellulose |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4585797A (en) | 1981-04-13 | 1986-04-29 | Seton Company | Cosmetic and pharmaceutical sheet material containing polypeptides |
US4376743A (en) | 1981-06-12 | 1983-03-15 | Fiber Industries, Inc. | Melt spinning process |
US4451589A (en) | 1981-06-15 | 1984-05-29 | Kimberly-Clark Corporation | Method of improving processability of polymers and resulting polymer compositions |
US4499223A (en) | 1981-10-17 | 1985-02-12 | Nippon Paint Co., Ltd. | Hydrolyzable polyester resins and coating compositions containing the same |
EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
DE3218151A1 (en) | 1982-05-14 | 1983-11-17 | Akzo Gmbh, 5600 Wuppertal | MICROPOROUS, POWDER-SHAPED POLYLACTIDES AND METHOD FOR THE PRODUCTION THEREOF |
US4595584A (en) | 1983-05-26 | 1986-06-17 | Eastman Kodak Company | Rumen-stable pellets |
US4687676A (en) | 1982-07-12 | 1987-08-18 | Eastman Kodak Company | Rumen-stable pellets |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4542025A (en) | 1982-07-29 | 1985-09-17 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4426500A (en) | 1982-08-23 | 1984-01-17 | Phillips Petroleum Company | Polymer solubilization |
JPS5966841A (en) | 1982-10-05 | 1984-04-16 | Meiji Seika Kaisha Ltd | Preparation of conjugate fibrous chewing gum |
US4469613A (en) | 1983-02-23 | 1984-09-04 | International Flavors & Fragrances Inc. | Detergent bar containing poly(epsilon caprolactone) and aromatizing agent |
US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
US4888176A (en) | 1984-05-21 | 1989-12-19 | Massachusetts Institute Of Technology | Controlled drug delivery high molecular weight polyanhydrides |
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4886870A (en) | 1984-05-21 | 1989-12-12 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4891225A (en) | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4779806A (en) | 1984-07-23 | 1988-10-25 | Massachusetts Institute Of Technology | Ultrasonically modulated polymeric devices for delivering compositions |
DE3428640A1 (en) | 1984-08-03 | 1986-02-06 | Akzo Gmbh, 5600 Wuppertal | MICROPOROUS, POWDER-SHAPED POLYLACTIDES |
US4637931A (en) | 1984-10-09 | 1987-01-20 | The United States Of America As Represented By The Secretary Of The Army | Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material |
US4634720A (en) | 1985-02-19 | 1987-01-06 | The Dow Chemical Company | Process for the preparation of hard tissue prosthetics |
JPS61291984A (en) | 1985-06-18 | 1986-12-22 | Ichiro Shibauchi | Production of rustproof material |
US4780319A (en) | 1985-07-08 | 1988-10-25 | Merck & Co., Inc. | Organic acids as catalysts for the erosion of polymers |
US4889119A (en) | 1985-07-17 | 1989-12-26 | Ethicon, Inc. | Surgical fastener made from glycolide-rich polymer blends |
US4686790A (en) | 1985-10-29 | 1987-08-18 | Kuwait Institute For Scientific Research | Degradable agricultural plastic articles, e.g., mulching film, comprising slowly released multinutrients in matrix of thermoplastic, and process for preparing same |
US4717567A (en) | 1985-11-25 | 1988-01-05 | Eastman Kodak Company | Rumen-stable pellets |
GB2187193B (en) | 1986-02-27 | 1989-11-08 | Gerald Scott | Controllably and swiftly degradable polymer compositions and films and other products made therefrom |
US4789724A (en) | 1986-10-17 | 1988-12-06 | Massachusetts Institute Of Technology | Preparation of anhydride copolymers |
US4719246A (en) | 1986-12-22 | 1988-01-12 | E. I. Du Pont De Nemours And Company | Polylactide compositions |
FR2610635B1 (en) | 1987-02-10 | 1989-06-23 | Extrusion Calandrage Ste Fse | POLYURETHANE COMPOSITIONS FOR CALENDERING BIODEGRADABLE MATERIALS |
CH671961A5 (en) | 1987-02-27 | 1989-10-13 | Amrotex Ag | |
US4985251A (en) | 1987-04-01 | 1991-01-15 | Lee County Mosquito Control District | Flowable insecticidal delivery compositions and methods for controlling insect populations in an aquatic environment |
US4855326A (en) | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
US4997856A (en) | 1987-04-20 | 1991-03-05 | Fuisz Pharmaceutical Ltd. | Method of producing compacted dispersable systems |
US5034421A (en) | 1988-12-13 | 1991-07-23 | Fuisz Pharmaceutical Ltd. | Moderated spun fibrous system and method of manufacture |
US4873085A (en) | 1987-04-20 | 1989-10-10 | Fuisz Pharmaceutical Ltd. | Spun fibrous cosmetic and method of use |
US5096492A (en) | 1987-04-20 | 1992-03-17 | Fuisz Technologies Ltd. | Dispersed systems and method of manufacture |
US5028632A (en) | 1987-04-20 | 1991-07-02 | Fuisz Pharmaceutical Ltd. | Taste masked medicated pharmaceutical |
US5011532A (en) | 1988-03-18 | 1991-04-30 | Fuisz Pharmaceutical Ltd. | Dispersed systems and method of manufacture |
RU2056835C1 (en) | 1987-04-20 | 1996-03-27 | Фьюиз Фармасьютикал Лтд. | Method of preparing soluble medicinal agent |
US4861627A (en) | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
US4857311A (en) | 1987-07-31 | 1989-08-15 | Massachusetts Institute Of Technology | Polyanhydrides with improved hydrolytic degradation properties |
US4933431A (en) | 1987-07-31 | 1990-06-12 | Massachusetts Institute Of Technology | One step preparation of poly(amide-anhydride) |
JPS6465129A (en) | 1987-09-04 | 1989-03-10 | Mitsubishi Gas Chemical Co | Production of aromatic polyether |
DE3730487A1 (en) | 1987-09-11 | 1989-03-23 | Hollingsworth Gmbh | DEVICE FOR REMOVING FIBER GOODS, ESPECIALLY BALLS OF SPINNING GOODS |
US4839450A (en) | 1987-11-17 | 1989-06-13 | The United States Of America As Represented By The Secretary Of Agriculture | Moisture-shrinkable films from starch graft copolymers |
IT1216719B (en) | 1988-01-28 | 1990-03-08 | Milano | THERMODEGRADABLE COMPOSITIONS ABASE OF OMO OR CRYSTALLINE COPOLYMERS OF PROPYLENE AND PROCEDURE TO PERFORM THE SELECTIVE DEGRADATION OF SUCH OMO AND COPOLYMERS. |
US4898734A (en) | 1988-02-29 | 1990-02-06 | Massachusetts Institute Of Technology | Polymer composite for controlled release or membrane formation |
US4891404A (en) | 1988-05-27 | 1990-01-02 | Purdue Research Foundation | Biodegradable graft copolymers |
US4999417A (en) | 1989-03-30 | 1991-03-12 | Nova Pharmaceutical Corporation | Biodegradable polymer compositions |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
US5070122A (en) | 1989-06-15 | 1991-12-03 | Eastman Kodak Company | Environmentally degradable polymer blends |
US4983645A (en) | 1989-07-11 | 1991-01-08 | Mobil Oil Corporation | Photoinitiators as light sensitive degradants for polyethylene |
US4997904A (en) | 1989-08-25 | 1991-03-05 | Nova Pharmaceutical Corporation | Aromatic polyanhydride compositions |
US5015293A (en) | 1989-09-18 | 1991-05-14 | The United States Of America As Represented By The Secretary Of The Army | Method of forming a crosslinked chitosan polymer and product thereof |
ZA908406B (en) | 1990-10-19 | 1991-08-28 | Fuisz Pharmaceutical Ltd | Taste masked medicated floss |
HUT68509A (en) * | 1991-05-17 | 1995-06-28 | Fuisz Technologies Ltd | New thermoplastic polymeric material and process for making same |
-
1992
- 1992-06-03 US US07/893,238 patent/US5518730A/en not_active Expired - Lifetime
-
1993
- 1993-06-02 AU AU44058/93A patent/AU665844B2/en not_active Ceased
- 1993-06-02 CA CA002137268A patent/CA2137268A1/en not_active Abandoned
- 1993-06-02 JP JP50087794A patent/JP3941878B2/en not_active Expired - Fee Related
- 1993-06-02 DE DE69332210T patent/DE69332210T2/en not_active Expired - Lifetime
- 1993-06-02 WO PCT/US1993/005307 patent/WO1993024154A1/en active IP Right Grant
- 1993-06-02 EP EP93914373A patent/EP0746342B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU4405893A (en) | 1993-12-30 |
DE69332210T2 (en) | 2003-04-24 |
DE69332210D1 (en) | 2002-09-19 |
EP0746342B1 (en) | 2002-08-14 |
US5518730A (en) | 1996-05-21 |
EP0746342A1 (en) | 1996-12-11 |
AU665844B2 (en) | 1996-01-18 |
JPH07507548A (en) | 1995-08-24 |
JP3941878B2 (en) | 2007-07-04 |
EP0746342A4 (en) | 1996-01-11 |
WO1993024154A1 (en) | 1993-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU665844B2 (en) | Biodegradable controlled release melt-spun delivery system | |
ES2278466T3 (en) | DOSAGE FORMS CONTAINING ACTIVE AGENTS OF MASKED FLAVOR. | |
US6048541A (en) | Fast-dissolving comestible units formed under high-speed/high-pressure conditions | |
CN110870846A (en) | Rapidly implantable sustained-release microneedle patch and preparation method thereof | |
EP1066032B1 (en) | Sachet formulations | |
US6391338B1 (en) | System for rendering substantially non-dissoluble bio-affecting agents bio-available | |
US6086920A (en) | Disintegratable microspheres | |
US6319512B1 (en) | Implants for controlled release of pharmaceutically active principles and method for making same | |
US20060068021A1 (en) | Sustained-release microencapsulated delivery system | |
US5980941A (en) | Self-binding shearform compositions | |
KR100289471B1 (en) | A controlled/sustained implant delivery containing fentanyls | |
JP2011079864A (en) | Quick dissolve compositions and tablets based thereon | |
WO1992015285A1 (en) | Starch-based controlled release compositions | |
EP0952770A1 (en) | System for rendering substantially non-dissoluble bio-affecting agents bio-available | |
AU710539B2 (en) | Pharmaceutical compositions for the sustained release of insoluble active principles | |
US20120164207A1 (en) | Degradable networks for sustained release and controlled release depot drug delivery applications | |
CA2348452A1 (en) | Microparticles containing peg and/or peg glyceryl esters | |
CN1226584A (en) | The production of solid dosage forms | |
JP2002528042A (en) | Dosage forms with improved release characteristics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |